Vortex mixers and associated methods, systems, and apparatuses thereof

A two-stage vortex mixer system addresses the inefficiencies of single-stage mixers by separating the formation of empty nanoparticles and nucleic acid incorporation, ensuring effective mixing and preventing degradation while reducing fouling.

JP2024161062AActive Publication Date: 2024-11-15MODERNATX INC
View PDF 9 Cites 0 Cited by

Patent Information

Application Number
JP2024141728
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-08-14
Filing Date
2024-08-23
Publication Date
2024-11-15
Estimated Expiration
2040-01-31

AI Technical Summary

Technical Problem

Existing vortex mixers face challenges in efficiently mixing multiple fluids without causing premature nucleic acid degradation and fouling, particularly when combining lipids and nucleic acids, due to unsuitable mixing geometries and exposure to acidic buffers.

Method used

A two-stage vortex mixer system is employed, where a first stage mixes lipids and ethanol to form empty nanoparticles, followed by a second stage that incorporates nucleic acids into these nanoparticles, minimizing direct exposure to acidic buffers and reducing fouling.

Benefits of technology

This approach effectively prevents nucleic acid degradation and reduces fouling, resulting in better encapsulation of nucleic acids into lipid nanoparticles, enhancing mixing efficiency and stability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024161062000001_ABST
    Figure 2024161062000001_ABST
Patent Text Reader

Abstract

To provide a vortex mixer having a plurality of inlet ports and an associated method, system, and apparatus thereof.SOLUTION: A vortex mixer (400) may have a vortex mixing chamber (450) having a first wall (451), a second wall (452), and a side wall (453) connecting the first wall and the second wall. At least two inlet ports (405, 410, 415, 520) may be configured along the side wall, each inlet port having an inlet channel connected thereto. The at least two inlet ports may be approximately equally spaced around the vortex mixing chamber and configured tangentially to the vortex mixing chamber. An exit port (455) may have an exit channel connected thereto. The exit port may be configured at a radial center of the second wall, and the exit channel may extend from the exit port and away from the vortex mixing chamber.SELECTED DRAWING: Figure 4A
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to and the benefit of U.S. Provisional Application No. 62 / 799,636, entitled "VORTEX MIXERS AND ASSOCIATED METHODS, SYSTEMS, AND APPARATUSES THEREOF," filed January 31, 2019, and U.S. Provisional Application No. 62 / 886,592, entitled "VORTEX MIXERS AND ASSOCIATED METHODS, SYSTEMS, AND APPARATUSES THEREOF," filed August 14, 2019. The disclosures of the above U.S. provisional applications are incorporated herein by reference in their entireties.

[0002] INCORPORATION BY REFERENCE TO SEQUENCE LISTING The contents of the text file named "MRNA-064001WO_Sequence_Listing.txt", created on January 30, 2020 and having a size of 688B, are hereby incorporated by reference in their entirety.

[0003] Field of the Disclosure The present disclosure relates to vortex mixers and related methods, systems, and apparatus. [Background technology]

[0004] A vortex mixer spins a fluid at high speeds to create changes in the fluid. A vortex mixer can accept multiple fluids and can be used to mix multiple fluids. In a vortex mixer with multiple inlets, the vortex mixer can accept two or more fluids and can be used to mix the fluids. Summary of the Invention

[0005] Some embodiments of the present disclosure provide a vortex mixer and related methods, systems, and apparatus. In some embodiments, the vortex mixer may have a vortex mixing chamber having a first wall, a second wall, and a side wall connecting the first wall and the second wall. At least two inlets may be configured along the side wall, and an inlet channel may be connected to each inlet. The at least two inlets may be approximately equally spaced around the vortex mixing chamber and may be configured tangentially to the vortex mixing chamber. An outlet may be configured at a radial center of the second wall, with an outlet channel connected thereto. The outlet channel may extend from the outlet and extend away from the vortex mixing chamber.

[0006] In some embodiments, the vortex mixing chamber can be round and the side wall can extend around the perimeter of the first wall and the second wall. Each inlet channel may receive fluid from a single source, or each inlet channel may receive fluid from a different source.

[0007] In some embodiments, the vortex mixer may have four inlets. The first two of the four inlets may receive a fluid from a first source, while the second two of the four inlets may receive a fluid from a second source. The first two inlets may be configured opposite each other, and the second two inlets may be configured opposite each other, such that each of the first two inlets is about 90 degrees away from each of the second two inlets, while the first two inlets are about 180 degrees apart and the second two inlets are about 180 degrees apart. Alternatively, each of the four inlets may receive a fluid from a separate source. The first two of the four inlets may receive a first fluid, and the second two of the four inlets may receive a second fluid. The first two inlets are configured opposite one another and the second two inlets are configured opposite one another such that the first two inlets are approximately 180 degrees apart and the second two inlets are approximately 180 degrees apart and each of the first two inlets is approximately 90 degrees apart from each of the second two inlets.

[0008] The outlet and outlet channel may be at an angle of about 90 degrees from the second wall. In some embodiments, the height of the sidewall may be the same as the height of the at least two inlets. In other implementations, the height of the sidewall may be greater than the height of the at least two inlets.

[0009] In some embodiments, the diameter of the outlet can be x, the diameter of the first and second walls can be 5*x, the height of the side wall can be 1.75*x, and the height of the at least two inlets can be 0.75*x. In various implementations, the value of x can be 1 mm, 2 mm, 4 mm, 5 mm, or 0.5 mm.

[0010] The mixing system may include a first vortex mixer and a subsequent vortex mixer. The first vortex mixer may include a vortex mixing chamber having a first wall, a second wall, and a side wall connecting the first wall and the second wall. At least two inlets may be configured along the side wall, with an inlet flow path connected to each inlet. The at least two inlets may be equally spaced around the vortex mixing chamber and configured tangentially to the vortex mixing chamber. An outlet may be configured at a radial center of the second wall, with an outlet flow path connected thereto. The flow path may extend from the outlet and away from the vortex mixing chamber.

[0011] The subsequent vortex mixer may have a vortex mixing chamber having a first wall, a second wall, and a side wall connecting the first wall and the second wall. At least two inlets may be configured along the side wall, with an inlet flow path connected to each inlet. The at least two inlets may be approximately equally spaced around the vortex mixing chamber and configured tangentially to the vortex mixing chamber. The subsequent vortex mixer may also have an additional inlet and an outlet with an outlet flow path connected thereto. The outlet may be configured in the center of the second wall, and the flow path may extend from the outlet and away from the vortex mixing chamber.

[0012] In some embodiments, the additional inlet may be configured at the radial center of the first wall of the subsequent vortex mixer. The additional inlet may be connected to a flow path extending from the initial vortex mixer outlet.

[0013] A flow divider may be configured at an end of an outlet flow path extending from the first vortex mixer outlet, the flow divider may have a first outlet and a second outlet. The first outlet may be connected to a first inlet of the at least two inlets, and the second outlet may be connected to a second inlet of the at least two inlets. The additional inlets may be connected to additional inlet flow paths.

[0014] In some embodiments, the subsequent vortex mixer may include a second additional inlet. The additional inlet and the second additional inlet may be arranged along the sidewall, and the additional inlet and the second additional inlet may be arranged approximately equally spaced around the vortex mixing chamber and tangential to the vortex mixing chamber. In some embodiments, the subsequent vortex mixer has two inlets, an additional inlet, and a second additional inlet, each of which is spaced around the vortex mixing chamber such that the inlets are each about 90 degrees apart. Some embodiments also include a second flow divider, the second flow divider having a first outlet connected to the additional inlet and a second outlet connected to the second additional inlet.

[0015] The diameter of the first vortex mixer outlet may be x, the diameter of the first wall of the first vortex and the second wall of the first vortex may be 5*x, the height of the side wall of the first vortex may be 1.75*x, and the height of each of the at least two first vortex inlets may be 0.75*x. The diameter of the subsequent vortex mixer outlet may be y, the diameter of the first wall of the subsequent vortex mixer and the second wall of the subsequent vortex mixer may be 5*y, the height of the side wall of the subsequent vortex mixer may be 1.75*y, and the height of each of the at least two subsequent vortex mixer inlets may be 0.75*y. In some embodiments, x and y may be exactly or approximately equal. In other embodiments, x may be greater than y.

[0016] The first vortex mixer and the subsequent vortex mixer may be made of at least one of stainless steel, PEEK, LFEM, acrylic, 3D printing media, and additive manufacturing materials. The first vortex mixer and the subsequent vortex mixer may be made of the same material.

[0017] The first vortex mixer outlet and the first vortex outlet passage may be at an angle of approximately 90 degrees from the second wall of the first vortex, and the subsequent vortex mixer outlet and the subsequent vortex outlet passage may be at an angle of approximately 90 degrees from the second wall of the subsequent vortex.

[0018] The mixing method may include receiving a first fluid in a first vortex mixing chamber from at least two inlets and receiving a second fluid in the first vortex mixing chamber from at least two inlets. The first and second fluids may be mixed in the first vortex mixing chamber to generate a first outlet fluid, and the first outlet fluid may flow into a first outlet flow path. The first outlet fluid may be split into at least two flow paths by a flow splitter. The first outlet fluid may be received in a second vortex mixing chamber from at least two inlets connected to the at least two flow paths. A third fluid may be received in the second vortex mixing chamber, and the outlet fluid and the third fluid may be mixed in the second vortex mixing chamber to generate a second outlet fluid. The second outlet fluid may flow into a second outlet flow path.

[0019] In some embodiments, the first fluid may include a buffer, the second fluid may include a lipid mixture, and the first outflow fluid may include empty nanoparticles. The third fluid may include nucleic acid (e.g., RNA), and the second outflow fluid may include nucleic acid-carrying nanoparticles. The nucleic acid may be incorporated into the nanoparticles by hydrophobic and / or charge interactions. By forming empty nanoparticles in the first vortex mixing chamber before the nucleic acid is received in the second vortex mixing chamber, the nucleic acid may be prevented from being directly exposed to the buffer before the buffer is mixed with the lipid mixture. By preventing the nucleic acid from being directly exposed to the buffer, acidification and / or degradation of the nucleic acid may be prevented.

[0020] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Patent and Trademark Office upon request and payment of the necessary fee. [Brief description of the drawings]

[0021] [Figure 1A] 1 illustrates a vortex mixer according to some embodiments. [Figure 1B] 1 illustrates a vortex mixer according to some embodiments. [Figure 1C] 1 illustrates a vortex mixer according to some embodiments. [Figure 1D] 1 illustrates a vortex mixer according to some embodiments. [Figure 1E] 1 illustrates a vortex mixer according to some embodiments. [Diagram 2] 1 illustrates a vortex mixer according to some embodiments. [Diagram 3] AB show a vortex mixer according to some embodiments. [Figure 4A] 1 illustrates a vortex mixer according to some embodiments. [Figure 4B] 1 illustrates a vortex mixer according to some embodiments. [Figure 4C] 1 illustrates a vortex mixer according to some embodiments. [Diagram 5] 1 illustrates a two-stage vortex mixer according to some embodiments. [Figure 6] AB show a two-stage vortex mixer according to some embodiments. [Figure 7] AB show a two-stage vortex mixer according to some embodiments. [Figure 8] 1 illustrates a two-stage mixer according to some embodiments. [Figure 9] AB show a two-stage vortex mixer according to some embodiments. [Figure 10] 1 illustrates a two-stage vortex mixer according to some embodiments. [Figure 11] 1A-D show a vortex mixer system according to some embodiments. [Figure 12]1 illustrates a vortex mixer system according to some embodiments. [Figure 13A] 1 illustrates a vortex mixer according to some embodiments. [Figure 13B] 1 illustrates a time versus pressure plot according to some embodiments. [Figure 13C] 1 shows the mass fraction at the mid-chamber and the mass fraction at the first and second walls of a vortex mixer according to some embodiments. [Figure 14-1] AB show a vortex mixer according to some embodiments. [Figure 14-2] FIG. 13C shows a pressure versus time plot for the vortex mixer of FIGS. 13A-B. [Figure 14-3] DF show vortex mixers according to some embodiments. [Figure 15A] 1 illustrates mixing within a vortex mixing chamber at various scales according to some embodiments. [Figure 15B] 1 illustrates mixing within a vortex mixing chamber at various scales according to some embodiments. [Figure 15C] 1 illustrates mixing within a vortex mixing chamber at various scales according to some embodiments. [Figure 15D] 15A-15C show graphs of mixing time scale as a function of inflow velocity according to some embodiments. [Figure 15E-1] 14A-14B show mass fractions of the vortex mixer. [Figure 15E-2] Same as above. [Figure 16A] 1 illustrates various tables and graphs according to some embodiments. [Figure 16B] 1 illustrates various tables and graphs according to some embodiments. [Figure 16C] 1 illustrates various tables and graphs according to some embodiments. [Figure 16D] 1 illustrates various tables and graphs according to some embodiments. [Figure 16E]1 illustrates various tables and graphs according to some embodiments. [Figure 16F] 1 illustrates various tables and graphs according to some embodiments. [Figure 16G] 1 illustrates various tables and graphs according to some embodiments. [Figure 16H] 1 illustrates various tables and graphs according to some embodiments. [Figure 16I] 1 illustrates various tables and graphs according to some embodiments. [Figure 16J] 1 illustrates various tables and graphs according to some embodiments. [Figure 16K] 1 illustrates various tables and graphs according to some embodiments. [Figure 16L] 1 illustrates various tables and graphs according to some embodiments. [Figure 16M] 1 illustrates various tables and graphs according to some embodiments. [Figure 16N] 1 illustrates various tables and graphs according to some embodiments. [Figure 17A] 4 illustrates performance characteristics of several embodiments of a dual stage mixer. [Figure 17B] 4 illustrates performance characteristics of several embodiments of a dual stage mixer. [Figure 17C] 4 illustrates performance characteristics of several embodiments of a dual stage mixer. [Figure 17D] 4 illustrates performance characteristics of several embodiments of a dual stage mixer. [Figure 18A] 1 illustrates an exemplary fluid flow path within a vortex mixer. [Figure 18B] 1 illustrates an exemplary fluid flow path within a vortex mixer. [Figure 19] A to B show the mixture ratio as a function of time. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0022] FIG. 1A illustrates an exemplary embodiment of a vortex mixer 100. The vortex mixer 100 may have a vortex mixing chamber 150 having a first wall 151, a second wall 152, and a side wall 153 connecting the first wall 151 and the second wall 152. In some embodiments, the vortex mixing chamber 150 is round. That is, the first wall 151 and the second wall 152 are circular, and the side wall 153 extends around the circumference of the circle and connects the outer edges of the first wall 151 and the second wall 152. The vortex mixer 100 of FIG. 1A has four inlet channels 105, 110, 115, 120. In other implementations, the vortex mixer 100 may have more or fewer inlet channels. The inlet channels 105, 110, 115, 120 connect to a sidewall 152 of the vortex mixing chamber 150 via inlets 125, 130, 135, 140. The inlets 125, 130, 135, 140 may be precisely or approximately equally spaced around the vortex mixing chamber 150 such that fluid flowing through the inlet channels 105, 110, 115, 120 enters the vortex mixing chamber 150 tangentially. In other embodiments, the inlets 125, 130, 135, 140 and inlet channels 105, 110, 115, 120 may be configured non-tangentially. The inlets 125, 130, 135, 140 and inlet channels 105, 110, 115, 120 may be configured tangentially to the vortex mixing chamber 150, normal to the vortex mixing chamber 150, or at any angle in between. An outlet (not shown) is connected to the second wall 152 of the vortex mixing chamber 150, to which an outlet channel 160 is connected. The outlet may be configured at the center of the second wall 152, such as at the radial center. Fluid exits the vortex mixing chamber 150 via the outlet and exits through the outlet channel 160. The outlet channel 160 may be configured at a right angle (i.e., about 90 degrees) from the wall surface of the second wall 152. In some embodiments, the inlet 125 may receive a first fluid, the inlet 130 may receive a second fluid, the inlet 135 may receive a third fluid, and the inlet 140 may receive a fourth fluid. In some embodiments, the first fluid is the same as, or substantially similar to, the third fluid.In some embodiments, the second fluid is the same as, or substantially similar to, the fourth fluid.

[0023] In some embodiments, the inlet channels 105, 110, 115, 120 may receive fluid from a single source. In other embodiments, the inlet channels 105, 110, 115, 120 may receive fluid from different sources. For example, the inlet channels 105, 110, 115, 120 may each receive fluid from different sources, or some inlet channels may receive fluid from the same source while other inlet channels receive fluid from different sources. Thus, in some embodiments, two of the inlet channels may receive fluid from a first source and the other two inlet channels may receive fluid from a second source. Alternatively, three of the inlet channels may receive fluid from a first source and a fourth inlet channel may receive fluid from a second source, or two inlet channels may receive fluid from a first source, a third inlet channel may receive fluid from a second source, and a fourth inlet channel may receive fluid from a third source.

[0024] In an exemplary embodiment, two flow paths receive fluid from a first source and two flow paths receive fluid from a second source. In such an embodiment, the two flow paths receiving fluid from the first source may be adjacent to each other or may face each other. Correspondingly, the two flow paths receiving fluid from the second source may be adjacent to each other or may face each other.

[0025] In the embodiment shown in FIG. 1A, the first inlet channel 105 and the third inlet channel 115 are configured opposite each other. The first inlet channel 105 and the third inlet channel 115 are each about 90 degrees from the second inlet channel 110 and the fourth inlet channel 120. The first inlet channel 105 and the third inlet channel 115 carry a first fluid toward the vortex mixing chamber 150, and the second inlet channel 110 and the fourth inlet channel 120 carry a second fluid toward the vortex mixing chamber 150. The first inlet channel 105 and the third inlet channel 115 may receive the first fluid from a common first fluid source or from different sources of the first fluid. Similarly, the second inlet channel 110 and the fourth inlet channel 120 may receive the second fluid from a common second fluid source or from different sources of the second fluid.

[0026] A first fluid and a second fluid are received within the vortex mixing chamber 150. In some embodiments, the first fluid and the second fluid rotate within the vortex mixing chamber 150, at least in part, as the fluids enter the vortex mixing chamber 150 tangentially through the inlets 125, 130, 135, 140. As the first and second fluids mix within the vortex mixing chamber 150, the mixed fluids flow through the outlet and into the outlet channel 160.

[0027] Figure 1B illustrates an exploded view of an embodiment of vortex mixer 100. As shown in Figure 1B, vortex mixer 100 is composed of two parts: a cover 165 and a mixer component 170. Cover 165 has inlets 166, 167, 168, 169 that correspond to inlet channels 105, 110, 115, 120. Inlets 166, 167, 168, 169 are configured to receive fluid from a fluid source in any of the configurations previously described with respect to Figure 1A.

[0028] 1C illustrates an exemplary configuration in which inlets 166 and 168 receive fluid from a first source and inlets 167 and 169 receive fluid from a second source. Fluid from the first source enters inlets 166, 168 through a first fluid diverter 171, and fluid from the second source enters inlets 167, 169 through a second fluid diverter 173.

[0029] Fluid enters inlet channels 105, 110, 115, 120 through inlets 166, 167, 168, 169 and then travels through inlet channels 105, 110, 115, 120 and through inlets 125, 130, 135, 140 into vortex mixing chamber 150. The assembled configuration of Figure 1B is shown as Figure 1D. Figure 1D also shows outlet 155 within vortex mixing chamber 150. Figure 1E shows a top view of Figure 1D.

[0030] FIG. 2 shows an alternative embodiment of the vortex mixer 200. In this embodiment, the vortex mixer 200 includes internal flow dividers 271, 273. The internal flow dividers 271, 273 may be used instead of the external flow dividers shown in FIG. 1C. In this embodiment, the cover 265 has two inlets 266, 267. A first fluid from the inlet 266 enters the flow divider channel 272 of the internal flow divider 271. The flow divider channel 272 divides the first fluid and sends the first fluid to the inlet channels 205, 215. Meanwhile, a second fluid from the inlet 267 enters the flow divider channel 274 of the internal flow divider 273. The flow divider channel 274 divides the second fluid and sends the second fluid to the inlet channels 210, 220. Once the first and second fluids enter the inlet channels 205, 210, 215, 220 of the mixer element 270, the vortex mixer 200 operates as described above with respect to Figures 1A-1E.

[0031] FIG. 3A shows an exploded view of the alternative embodiment of FIG. 2. In the embodiment of FIG. 3A, the internal flow dividers 371, 373 and mixer component 370 operate in the same manner as in the embodiment of FIG. 2. However, the cover 365 receives fluid at inlets 366, 367. A first fluid enters the inlet 366 and is transported by the internal fluid flow paths to the internal flow divider 371. Similarly, a second fluid enters the inlet 367 and is transported by the internal fluid flow paths to the internal flow divider 373. As the fluid enters the internal flow dividers 371 and 373 through the flow divider channels 372 and 374, respectively, the fluid is diverted and enters the inlet channels 305, 310, 315, 320 as described above. The vortex mixing chamber 350 and the outlet 355 are also shown, which are fluidly coupled to the external outlet 399. FIG. 3B shows the embodiment of FIG. 3A with the cover 365, internal flow dividers 371, 373, and mixer component 370 assembled.

[0032] FIG. 4A illustrates an exemplary embodiment of a vortex mixer 400. The vortex mixer 400 may have a vortex mixing chamber 450 having a first wall 451, a second wall 452, and a side wall 453 connecting the first wall 451 and the second wall 452. In some embodiments, the vortex mixing chamber 450 is round. That is, the first wall 451 and the second wall 452 are circular, and the side wall 453 extends around the circumference of the circle and connects the outer edges of the first wall 451 and the second wall 452. The vortex mixer 400 of FIG. 4A has four inlet channels 405, 410, 415, 420. In other implementations, the vortex mixer 400 may have more or fewer inlet channels. The inlet channels 405, 410, 415, 420 connect to a sidewall 452 of the vortex mixing chamber 450 via inlets 425, 430, 435, 440. The inlets 425, 430, 435, 440 may be precisely or approximately equally spaced around the vortex mixing chamber 450 such that fluid flowing through the inlet channels 405, 410, 415, 420 enters the vortex mixing chamber 450 tangentially. In other embodiments, the inlets 425, 430, 435, 440 and inlet channels 405, 410, 415, 420 may be configured non-tangentially. The inlets 425, 430, 435, 440 and inlet channels 405, 410, 415, 420 may be configured tangentially to the vortex mixing chamber 450, normal to the vortex mixing chamber 450, or at any angle in between. An outlet (not shown) is connected to the second wall 452 of the vortex mixing chamber 450, to which an outlet channel 460 is connected. The outlet may be configured at the center of the second wall 452, such as at the radial center. Fluid exits the vortex mixing chamber 450 via the outlet and exits through the outlet channel 460. The outlet channel 460 may be configured at a right angle (i.e., approximately 90 degrees) from the surface of the second wall 452.

[0033] A fifth inlet channel 478 may be configured to receive a fifth fluid. The third inlet channel 478 may be fluidly connected to the vortex mixing chamber 450 via the fifth inlet 458. The fifth inlet 458 may be configured in a first wall 451 of the vortex mixing chamber 450. In some embodiments, the fifth inlet 458 may be configured in a center of the first wall 451, such as a radial center of the first wall 451. The third inlet 458 may be configured in a second wall 452 of the vortex mixing chamber 450. In some embodiments, the fifth inlet 458 may be configured in a center of the second wall 452, such as a radial center of the second wall 452. The first wall 451 and the second wall 452 are connected by a side wall 453. In some embodiments, the fifth inlet chamber 478 may have a diameter of about 0.1 times the diameter of the vortex mixer 400. In some embodiments, the outlet 455 may have a diameter that is about 0.2 times the diameter of the vortex mixer 400 .

[0034] 4B and 4C show an embodiment of a vortex mixer 400 and an exploded view of the vortex mixer, respectively. The vortex mixer 400 can have a vortex mixing chamber having a first wall 451, a second wall 452, and a side wall 453 connecting the first wall 451 and the second wall 452. In some embodiments, the vortex mixing chamber 450 is round. That is, the first wall 451 and the second wall 452 are circular, and the side wall 453 extends around the circumference of the circle and connects the outer edges of the first wall 451 and the second wall 452. The vortex mixer 400 of FIG. 4A has four inlet channels 405, 410, 415, 420. In other implementations, the vortex mixer 400 can have more or fewer inlet channels. The inlet channels 405, 410, 415, 420 connect to a sidewall 452 of the vortex mixing chamber 450 via inlets 425, 430, 435, 440. The inlets 425, 430, 435, 440 may be precisely or approximately equally spaced around the vortex mixing chamber 450 such that fluid flowing through the inlet channels 405, 410, 415, 420 enters the vortex mixing chamber 450 tangentially. In other embodiments, the inlets 425, 430, 435, 440 and inlet channels 405, 410, 415, 420 may be configured non-tangentially. The inlets 425, 430, 435, 440 and inlet channels 405, 410, 415, 420 may be configured tangentially to the vortex mixing chamber 450, normal to the vortex mixing chamber 450, or at any angle in between. Connected to the second wall 452 of the vortex mixing chamber 450 is an outlet 455 to which an outlet channel 460 is connected. The outlet 455 may be configured at the center of the second wall 452, such as at the radial center. Fluid exits the vortex mixing chamber 450 via the outlet 455 and exits through the outlet channel 460. The outlet channel 460 may be configured at a right angle (i.e., approximately 90 degrees) from the surface of the second wall 452.

[0035] A fifth inlet channel 478 may be configured to receive a fifth fluid. The third inlet channel 478 may be fluidly connected to the vortex mixing chamber 450 via the fifth inlet 458. The fifth inlet 458 may be configured in a first wall 451 of the vortex mixing chamber 450. In some embodiments, the fifth inlet 458 may be configured in a center of the first wall 451, such as a radial center of the first wall 451. The fifth inlet 458 may be configured in a second wall 452 of the vortex mixing chamber 450. In some embodiments, the fifth inlet 458 may be configured in a center of the second wall 452, such as a radial center of the second wall 452. The first wall 451 and the second wall 452 are connected by a side wall 453. In some embodiments, the fifth inlet chamber 478 may have a diameter of about 0.1 times the diameter of the vortex mixer 400. In some embodiments, the outlet 455 may have a diameter of about 0.2 times the diameter of the vortex mixer 400. In some embodiments, the inlet 425 may receive a first fluid, the inlet 430 may receive a second fluid, the inlet 435 may receive a third fluid, the inlet 440 may receive a fourth fluid, and the inlet 458 may receive a fifth fluid. In some embodiments, the first fluid is the same as, or substantially similar to, the third fluid. In some embodiments, the second fluid is the same as, or substantially similar to, the fourth fluid. In some embodiments, the first and third fluids may include lipids. In some embodiments, the first and third fluids may include ethanol. In some embodiments, the first and third fluids may include lipids. In some embodiments, the second and fourth fluids may include nucleic acids (e.g., RNA). In some embodiments, the second and fourth fluids may include ethanol. In some embodiments, the second fluid and the fourth fluid may comprise lipids. In some embodiments, the fifth fluid may comprise nucleic acids.

[0036] 5 illustrates an exemplary embodiment of a two-stage mixer 500. The first stage mixer 501 may be configured similarly to any of the vortex mixers described above. As illustrated, the first stage mixer 501 has a vortex mixing chamber 550 having a first wall 551, a second wall 552, and a sidewall 553 connecting the first wall 551 and the second wall 552. The vortex mixing chamber 550 may have four inlets 525, 530, 535, 540 configured along the sidewall 553. Each of the four inlets 525, 530, 535, 540 may receive fluid from a corresponding inlet channel 505, 510, 515, 520. The first inlet flow channel 505 and the third inlet flow channel 515 may receive a first fluid, and the second inlet flow channel 510 and the fourth inlet flow channel 520 may receive a second fluid. In some embodiments, each inlet flow channel 505, 510, 515, 520 may receive a fluid from a separate fluid source. In other implementations, the first inlet flow channel 505 and the third inlet flow channel 515 may receive a first fluid from a first fluid source. That is, the first fluid may pass through a first fluid diverter that directs the first fluid to the first inlet flow channel 505 and the third inlet flow channel 515. Correspondingly, the second inlet flow channel 510 and the fourth inlet flow channel 520 may receive a second fluid from a second fluid source. That is, the second fluid may pass through a second fluid diverter that directs the second fluid to the second inlet flow channel 510 and the fourth inlet flow channel 520. The first and second fluid flow dividers may be the internal or external flow dividers described above.

[0037] The first fluid flows in the first inlet channel 505 through the first inlet 525 and into the vortex mixing chamber 550 and in the third inlet channel 515 through the third inlet 535. The first inlet 525 and the third inlet 535 may be exactly or nearly 180 degrees from each other and may direct the first fluid so that it enters the vortex mixing chamber 550 tangentially. In other embodiments, the first inlet 525 and the third inlet 535 may direct the first fluid so that it enters the vortex mixing chamber 550 normally or at an angle between the tangential and the normal. Similarly, the second fluid flows through the second inlet channel 510 and into the vortex mixing chamber 550 through the second inlet 530 and through the fourth inlet channel 520 and into the vortex mixing chamber 550 through the fourth inlet 540. The second inlet 530 and the fourth inlet 540 may be exactly or nearly 180 degrees from each other and exactly or nearly 90 degrees from the first inlet 525 and the third inlet 535. The second inlet 530 and the fourth inlet 540 direct the second fluid to enter the vortex mixing chamber 550 tangentially, normally, or at any angle in between. In some embodiments, inlet 525 may receive a first fluid, inlet 530 may receive a second fluid, inlet 535 may receive a third fluid, and inlet 540 may receive a fourth fluid. In some embodiments, the first fluid is the same as or substantially similar to the third fluid. In some embodiments, the second fluid is the same as or substantially similar to the fourth fluid. In some embodiments, the first and third fluids may include lipids. In some embodiments, the first and third fluids may include ethanol. In some embodiments, the second and fourth fluids may include lipids. In some embodiments, the second and fourth fluids may include an acidic buffer. In some embodiments, the second and fourth fluids may include nucleic acids (e.g., RNA). In some embodiments, the second and fourth fluids may include ethanol.

[0038] The vortex mixing chamber 550 can have an outlet 555 connected to an outlet passage 560. The outlet may be configured in a second wall 552 of the vortex mixing chamber 550. The outlet may be configured in a center of the second wall 552, such as in a radial center. The outlet fluid from the first stage mixer 501 flows out of the vortex mixing chamber 550 via the outlet 555 and out through the outlet passage 560.

[0039] The first stage mixer outlet fluid flows out of first stage vortex mixing chamber 550 through outlet passage 560 and into flow diverter 561. Flow diverter 561 divides the first stage mixer outlet fluid and directs the first stage mixer outlet fluid to first inlet passage 575 through inlet 562 and to second inlet passage 577 through inlet 563 of second stage mixer 502. First inlet passage 575 and second inlet passage 577 are both connected to second stage vortex mixing chamber 580 via first inlet 585 and second inlet 586, respectively. The first inlet 585 and the second inlet 586 may be configured exactly or nearly 180 degrees apart and may be configured such that the first stage mixer outlet fluid enters the vortex mixing chamber 580 tangentially from each port 585, 586. In some embodiments, the first inlet 585 and the second inlet 586 may be configured such that the first stage mixer outlet fluid enters the vortex mixing chamber 580 at a normal angle to the vortex mixing chamber 580 or at any angle between normal and tangential to the vortex mixing chamber 580. A third inlet channel 578 may be configured to receive the second stage inlet fluid. The third inlet channel 578 may be fluidly connected to the second stage vortex mixing chamber 580 via a third inlet 588. The third inlet 588 may be configured in a first wall 581 of the vortex mixing chamber 580. In some embodiments, the third inlet 588 can be configured in a center of the first wall 581, such as a radial center of the first wall 581. The third inlet 588 can be configured in a second wall 582 of the vortex mixing chamber 580. In some embodiments, the third inlet 588 can be configured in a center of the second wall 582, such as a radial center of the second wall 582. The first wall 581 and the second wall 582 are connected by a side wall 583. In some embodiments, the third inlet 588 can receive a fifth fluid. In some embodiments, the fifth fluid can include nucleic acid.

[0040] The vortex mixing chamber 580 can have a second stage mixer outlet 589 connected to a second stage mixer outlet passage 590. The second stage mixer outlet may be configured at a center of the second wall 582, such as at a radial center. The outlet fluid from the second stage mixer 502 flows out of the vortex mixing chamber 580 via the second stage mixer outlet 589 and out through the second stage mixer outlet passage 590.

[0041] In some embodiments, the second stage mixer 502 may have the same or substantially the same geometry as the embodiment described in FIG. 4A with four inlet passages. In other words, the second stage mixer 502 may have a first inlet 585, a second inlet 586, a third inlet (not shown), and a fourth inlet (not shown). In some embodiments, the third inlet may be fluidly coupled to the third inlet passage (not shown), and the fourth inlet may be fluidly coupled to the fourth inlet passage (not shown). In some embodiments, the third inlet passage and the fourth inlet passage may include an inlet where fluid may be added to the second stage mixer. In some embodiments, the third inlet passage and the fourth inlet passage may be fluidly coupled to a flow divider 561, in which case the flow divider 561 would be a four-way flow divider.

[0042] 6A and 6B show an embodiment of a two-stage vortex mixing system 600. In this embodiment, a first vortex mixer 601 may operate in the same manner as the vortex mixer 300 of FIGS. 3A-3B. This first vortex mixer 601 includes internal flow dividers 671, 673. The internal flow dividers 671, 673 may be used instead of the external flow divider shown in FIG. 6B. In this embodiment, a cover 665 has two inlets 666, 667. A first fluid from the inlet 666 enters a flow divider channel 672 of the internal flow divider 671. The flow divider channel 672 divides the first fluid and sends the first fluid to the inlet channels 605, 615. Meanwhile, a second fluid from the inlet 667 enters a flow divider channel 674 of the internal flow divider 673. The diverter channel 674 divertes the second fluid and routes the second fluid to the inlet channels 610, 620. Once the first and second fluids enter the inlet channels 605, 610, 615, 620 of the mixer component 670, the first vortex mixer 601 operates as described above with respect to Figures 1A-2. After mixing occurs within the first vortex mixing chamber 650, the mixed fluids pass through the first vortex mixer outlet 655 and then exit the first vortex mixing chamber 650 through the first vortex mixer outlet channel 660. The first stage mixer outlet fluid then enters the diverter 661. The flow divider 661 divides the first stage mixer outlet fluid and directs the first stage mixer outlet fluid to the second vortex mixer 602 through two inlets 662 and 664 on the cover 663. The inlets 662 and 664 each feed the mixed fluid to a second stage fluid inlet channel 675 and 677, respectively, in the mixer component 676. The second stage fluid inlet channels 675 and 677 feed the fluid to the second stage vortex mixing chamber 680. A third inlet channel 678 may be configured to receive the second stage inlet fluid. The third inlet channel 678 may be fluidly connected to the second stage vortex mixing chamber 680 via a third inlet 688. After mixing has taken place within the second stage vortex mixing chamber 680, the product fluid can exit the second stage vortex mixing chamber 680 via the second stage mixer outlet 689 through the second stage mixer outlet passage 690.In some embodiments, inlet 666 may receive a first fluid, inlet 667 may receive a second fluid, and inlet 688 may receive a third fluid.

[0043] FIG. 7A shows an exploded view of a mixing system 700, an alternative embodiment of FIG. 6A. In the embodiment of FIG. 7A, the internal flow dividers 771, 773 and mixer components 770 operate in the same manner as in the embodiment of FIG. 6. However, the cover 765 receives fluid at inlets 766, 767. A first fluid enters the inlet 766 and is transported by the internal fluid flow paths to the internal flow divider 771. Similarly, a second fluid enters the inlet 767 and is transported by the internal fluid flow paths to the internal flow divider 773. As the fluid enters the internal flow dividers 771 and 773 through the flow divider channels 772 and 774, respectively, the fluid is diverted and enters the inlet channels 705, 710, 715, 720 as described above with reference to FIG. 6A. The initial vortex mixing chamber 750 and the outlet 755 are also shown. The first stage mixer outlet fluid then enters the diverter 761 through the diverter channel 759. The diverter 761 divertes the first stage mixer outlet fluid and directs the first stage mixer outlet fluid to second stage fluid inlet channels 775 and 777 in the mixer component 776. The second stage fluid inlet channels 775 and 777 feed the second stage vortex mixing chamber 780. A third inlet channel 778 may be configured to receive the second stage inlet fluid. The third inlet channel 778 may be fluidly connected to the second stage vortex mixing chamber 780 via a third inlet 788. The third inlet channel 778 is fluidly coupled to a third inlet 798. The third inlet 798 may be coupled to the mixer component 770. Second stage vortex mixing chamber 780 has a second stage vortex mixing chamber outlet 789 that is coupled to a second stage vortex mixing chamber outlet passage 790. The second stage vortex mixing chamber outlet passage 790 is fluidly coupled to an external outlet 799. Figure 7B shows the embodiment of Figure 7A with the cover 765, internal flow dividers 771, 773, 761, and mixer components 770, 776 assembled.

[0044] In each of these embodiments, the size of the vortex mixer may vary, and in some embodiments, the overall dimensions of the vortex mixer may be linearly and / or proportionally scalable.

[0045] Additionally, in each of these embodiments, the various layers (including but not limited to the cover, the flow divider(s), the mixer component(s), etc.) may be connected by screwing the layers together, by soft bonding (e.g., using a material that can be fused under pressure), or by any other connecting means. Alternatively, the various layers of each embodiment may be formed by additive manufacturing, such as 3D printing, and thus formed as layers and / or as a single unit.

[0046] In an exemplary embodiment, the first fluid may be lipids in ethanol (also referred to herein as lipid master mix) and the second fluid may be nucleic acid in buffer. The lipid master mix and nucleic acid in buffer may enter the vortex mixing chamber through alternating inlets. Thus, in an embodiment having four inlet channels / inlets, the lipid master mix may flow through the first inlet channel to the vortex mixing chamber through the first inlet. Nucleic acid in buffer may flow through the second inlet channel to the vortex mixing chamber through the second inlet. The lipid master mix may flow through the third inlet channel to the vortex mixing chamber through the third inlet. Nucleic acid in buffer may flow through the fourth inlet channel to the vortex mixing chamber through the fourth inlet. The first inlet may enter the vortex mixing chamber at exactly or near 0 degrees. The second inlet may be exactly or near 90 degrees. The third inlet may be exactly or near 180 degrees. The fourth inlet may be exactly or near 270 degrees. Mixing these two fluids in a vortex mixing chamber produces lipid nanoparticles containing nucleic acids.

[0047] FIG. 8 illustrates an embodiment of a two-stage mixer 800. The first stage mixer 801 may be configured similarly to any of the vortex mixers described above. As illustrated, the first stage mixer 801 has a vortex mixing chamber 850 having a first wall 851, a second wall 852, and a sidewall 853 connecting the first wall 851 and the second wall 852. The vortex mixing chamber 850 may have four inlets 825, 830, 835, 840 configured along the sidewall 853. Each of the four inlets 825, 830, 835, 840 may receive fluid from a corresponding inlet channel 805, 810, 815, 820. The first inlet channel 805 and the third inlet channel 815 may receive a first fluid, and the second inlet channel 810 and the fourth inlet channel 820 may receive a second fluid. In some embodiments, each inlet flow channel 805, 810, 815, 820 may receive fluid from a separate fluid source. In other implementations, the first inlet flow channel 805 and the third inlet flow channel 815 may receive a first fluid from a first fluid source. That is, the first fluid may pass through a first fluid diverter that directs the first fluid to the first inlet flow channel 805 and the third inlet flow channel 815. Correspondingly, the second inlet flow channel 810 and the fourth inlet flow channel 820 may receive a second fluid from a second fluid source. That is, the second fluid may pass through a second fluid diverter that directs the second fluid to the second inlet flow channel 810 and the fourth inlet flow channel 820. The first fluid diverter and the second fluid diverter may be the internal or external diverters described above.

[0048] The first fluid flows in the first inlet channel 805 through the first inlet 825 and into the vortex mixing chamber 850 and in the third inlet channel 815 through the third inlet 835. The first inlet 825 and the third inlet 835 may be exactly or nearly 180 degrees from each other and may direct the first fluid such that it enters the vortex mixing chamber 850 tangentially. In other embodiments, the first inlet 825 and the third inlet 835 may direct the first fluid such that it enters the vortex mixing chamber 850 normally or at an angle between the tangential and the normal. Similarly, the second fluid flows through the second inlet channel 810 and into the vortex mixing chamber 850 through the second inlet 830 and through the fourth inlet channel 820 and into the vortex mixing chamber 850 through the fourth inlet 840. The second inlet 830 and the fourth inlet 840 may be exactly or nearly 180 degrees from each other and exactly or nearly about 90 degrees from the first inlet 825 and the third inlet 835. The second inlet 830 and the fourth inlet 840 direct the second fluid to enter the vortex mixing chamber 850 tangentially, normally, or at any angle in between.

[0049] The vortex mixing chamber 850 may have an outlet (not shown) to which the outlet passage 860 is connected. The outlet may be configured in a second wall 852 of the vortex mixing chamber 850. The outlet may be configured in a center of the second wall 852, such as in a radial center. The outlet fluid from the first stage mixer 801 flows out of the vortex mixing chamber 850 via the outlet and out through the outlet passage 860.

[0050] The first stage mixer outlet fluid flows through the outlet passage 860 and into the second stage mixer 802. In the embodiment shown in FIG. 8, the second stage mixer 802 has a vortex mixing chamber 880. The vortex mixing chamber 880 has a first wall 881, a second wall 882, and a sidewall 883 connecting the first wall 881 and the second wall 882. The first stage mixer outlet fluid flows out of the outlet passage 860 and into the vortex mixing chamber 880 through a second stage mixer inlet 875. The second stage mixer inlet 875 may be configured in the first wall 881 of the vortex mixing chamber 880. In some embodiments, the second stage mixer inlet 875 may be configured in a center of the first wall 881, such as a radial center of the first wall 881.

[0051] The vortex mixing chamber 880 may have another inlet. In the embodiment shown in FIG. 8, the vortex mixing chamber 880 has two more inlets 876, 877. The two additional inlets 876, 877 may be configured to receive the second stage inlet fluid from two inlet channels 878, 879. The two additional inlets 876, 877 may be configured exactly or nearly 180 degrees from each other and may be configured to direct the fluid to enter the vortex mixing chamber 880 tangentially. In other embodiments, the two additional inlets 876, 877 may be configured to direct the fluid to enter the vortex mixing chamber 880 non-tangentially, such as at a normal angle or at any angle between the normal and the tangential. The second stage inlet fluid may be received from two separate fluid sources or may be received from a single fluid source and diverted by an internal or external diverter as described above. In some embodiments, inlet 825 may receive a first fluid, inlet 830 may receive a second fluid, inlet 835 may receive a third fluid, and inlet 840 may receive a fourth fluid. In some embodiments, the first fluid is the same as or substantially similar to the third fluid. In some embodiments, the second fluid is the same as or substantially similar to the fourth fluid. In some embodiments, the first fluid and the third fluid may comprise lipids. In some embodiments, the first fluid and the third fluid may comprise ethanol. In some embodiments, the second fluid and the fourth fluid may comprise nucleic acids. In some embodiments, the second fluid and the fourth fluid may comprise ethanol. In some embodiments, inlet 876 may receive a fifth fluid and inlet 877 may receive a sixth fluid. In some embodiments, the fifth fluid may be the same as or substantially similar to the sixth fluid. In some embodiments, the fifth fluid and the sixth fluid may comprise nucleic acids.

[0052] The vortex mixing chamber 880 can have a second stage mixer outlet 889 connected to a second stage mixer outlet passage 890. The second stage mixer outlet may be configured at a center of the second wall 882, such as at a radial center. The outlet fluid from the second stage mixer 802 flows out of the vortex mixing chamber 880 via the outlet and out through the second stage mixer outlet passage 890.

[0053] 9A-9B show an alternative embodiment of a two-stage mixer 900. The first stage mixer 901 is configured as the first stage mixer 801 of FIG. 8. As shown, the first stage mixer 901 has a vortex mixing chamber 950 having a first wall 951, a second wall 952, and a sidewall 953 connecting the first wall 951 and the second wall 952. The vortex mixing chamber 950 may have four inlets 925, 930, 935, 940 configured along the sidewall 953. Each of the four inlets 925, 930, 935, 940 may receive fluid from a corresponding inlet channel 905, 910, 915, 920. The first inlet flow channel 905 and the third inlet flow channel 915 may receive a first fluid, and the second inlet flow channel 910 and the fourth inlet flow channel 920 may receive a second fluid. In some embodiments, each inlet flow channel 905, 910, 915, 920 may receive a fluid from a separate fluid source. In other implementations, the first inlet flow channel 905 and the third inlet flow channel 915 may receive a first fluid from a first fluid source. That is, the first fluid may pass through a first fluid diverter that directs the first fluid to the first inlet flow channel 905 and the third inlet flow channel 915. Correspondingly, the second inlet flow channel 910 and the fourth inlet flow channel 920 may receive a second fluid from a second fluid source. That is, the second fluid may pass through a second fluid diverter that directs the second fluid to the second inlet flow channel 910 and the fourth inlet flow channel 920. The first and second fluid flow dividers can be internal or external flow dividers as described above. However, in the embodiment of Figures 9A-9B, the second stage mixer 902 is turned sideways such that the outlet flow path 960 from the first stage mixer 901 is configured to enter the second stage vortex mixing chamber 980 through a second stage mixer inlet 975 configured along a sidewall 983 of the vortex mixing chamber 980. The second stage mixer inlet 975 is configured such that the first stage mixer outlet fluid enters the second stage vortex mixing chamber 980 tangentially. In other embodiments, the second stage mixer inlet 975 may be configured such that the first stage mixer outlet fluid enters the second stage vortex mixing chamber 980 in a non-tangential direction, such as normal to the vortex mixing chamber 980 or at any angle between normal and tangent.In FIG. 9A, the second stage mixing chamber 980 also has a second inlet 976 configured along a sidewall 983 of the mixing chamber 980. The second inlet 976 has an inlet passage 978 connected thereto. The second inlet passage 978 receives the second stage inlet fluid. The second stage inlet fluid flows out of the inlet passage 978 and through the second inlet 976 into the mixing chamber 980. The second inlet 976 is configured such that the fluid flows tangentially into the mixing chamber 980. In the embodiment of FIG. 9B, the second inlet 976 is configured normal to the mixing chamber 980, and the second inlet passage 978 is connected to the second inlet 976. In other embodiments, the second inlet 976 may be configured such that the fluid flows into the mixing chamber 980 at any angle between the normal angle and the tangential angle. The second inlet 976 may be configured exactly or nearly 180 degrees from the inlet 975. The second stage mixer 902 may have a second stage outlet (not shown) that directs the second stage output fluid to the second stage outlet flow channel 990. In some embodiments, the inlet 925 may receive a first fluid, the inlet 930 may receive a second fluid, the inlet 935 may receive a third fluid, and the inlet 940 may receive a fourth fluid. In some embodiments, the first fluid is the same as, or substantially about the same as, the third fluid. In some embodiments, the second fluid is the same as, or substantially about the same as, the fourth fluid. In some embodiments, the first and third fluids may include lipids. In some embodiments, the first and third fluids may include ethanol. In some embodiments, the second and fourth fluids may include nucleic acids. In some embodiments, the second and fourth fluids may include ethanol.

[0054] 10 illustrates another alternative embodiment of a two-stage mixer 1000. A first stage mixer 1001 and a second stage mixer 1002 are each configured as the first stage mixer 801 of FIG. 8. As shown, the first stage mixer 1001 has a vortex mixing chamber 1050 having a first wall 1051, a second wall 1052, and a sidewall 1053 connecting the first wall 1051 and the second wall 1052. The vortex mixing chamber 1050 may have four inlets 1025, 1030, 1035, 1040 configured along the sidewall 1053. Each of the four inlets 1025, 1030, 1035, 1040 may receive fluid from a corresponding inlet channel 1005, 1010, 1015, 1020. The first inlet flow channel 1005 and the third inlet flow channel 1015 may receive a first fluid, and the second inlet flow channel 1010 and the fourth inlet flow channel 1020 may receive a second fluid. In some embodiments, each inlet flow channel 1005, 1010, 1015, 1020 may receive a fluid from a separate fluid source. In other implementations, the first inlet flow channel 1005 and the third inlet flow channel 1015 may receive the first fluid from the first fluid source. That is, the first fluid may pass through a first fluid diverter that directs the first fluid to the first inlet flow channel 1005 and the third inlet flow channel 1015. Correspondingly, the second inlet flow channel 1010 and the fourth inlet flow channel 1020 may receive the second fluid from a second fluid source. That is, the second fluid may pass through a second fluid diverter that directs the second fluid to the second inlet flow channel 1010 and the fourth inlet flow channel 1020. The first and second fluid diverters may be internal or external diverters as described above. Here, the first stage mixer outlet fluid flows out of the first stage vortex mixing chamber 1050 through the outlet flow channel 1060 and into the diverter 1061. The diverter 1061 diverges the first stage mixer outlet fluid and directs the first stage mixer outlet fluid to the first inlet flow channel 1075 and the third inlet flow channel 1077 of the second stage mixer 1002. The second stage inlet fluid flows into the second inlet flow channel 1076 and the fourth inlet flow channel 1078. The inlet fluid of the second stage may be received from two separate fluid sources, or may be received from a single fluid source and divided by an internal or external flow divider as described above.

[0055] The first inlet channel 1075, the second inlet channel 1076, the third inlet channel 1077, and the fourth inlet channel 1078 may be fluidly connected to the second stage vortex mixing chamber 1080 via the first inlet 1085, the second inlet 1086, the third inlet 1087, and the fourth inlet 1088, respectively. The first inlet channel 1075 may be configured in a sidewall 1081 of the vortex mixing chamber 1080. The first inlet, the second inlet, the third inlet, and the fourth inlet 1085, 1086, 1087, 1088 may each be approximately 90 degrees apart from each other around the circumference of the sidewall 1083. The first inlet 1085 and the third inlet 1087 may be opposite each other, i.e., approximately or exactly 180 degrees apart. The second inlet 1086 and the fourth inlet 1088 may be opposite each other, i.e., approximately or exactly 180 degrees apart. The first inlet 1085, the second inlet 1086, the third inlet 1087, and the fourth inlet 1088 may each be configured to direct fluid tangentially to the sidewall 1083 of the vortex mixing chamber 1080. In alternative embodiments, the inlets 1085, 1086, 1087, 1088 may be configured to direct fluid at a normal angle to the sidewall 1083, or the inlets 1085, 1086, 1087, 1088 may be configured to direct fluid at any angle between normal and tangential to the sidewall 1083. The second stage vortex mixing chamber 1080 may have a second stage mixer outlet 1089 to which a second stage mixer outlet passage 1090 is connected. The second stage mixer outlet may be configured at the center of the second wall 1082, such as at the radial center. The outlet fluid from the second stage mixer 1002 flows out of the vortex mixing chamber 1080 via the outlet and out through the second stage mixer outlet passage 1090. In some embodiments, the inlet 1025 may receive a first fluid, the inlet 1030 may receive a second fluid, the inlet 1035 may receive a third fluid, and the inlet 1040 may receive a fourth fluid. In some embodiments, the first fluid is the same as or substantially about the same as the third fluid. In some embodiments, the second fluid is the same as or substantially about the same as the fourth fluid.In some embodiments, the first fluid and the third fluid may include lipids. In some embodiments, the first fluid and the third fluid may include ethanol. In some embodiments, the second fluid and the fourth fluid may include nucleic acids. In some embodiments, the second fluid and the fourth fluid may include ethanol. In some embodiments, the inlet 1076 may receive a fifth fluid and the inlet 1077 may receive a sixth fluid. In some embodiments, the fifth fluid may be the same as or substantially similar to the sixth fluid. In some embodiments, the fifth fluid and the sixth fluid may include nucleic acids.

[0056] As noted above, in some implementations of the embodiments shown in Figures 5, 8, 9, and 10, the first stage mixer receives lipids in ethanol (lipid master mix) and an acidic buffer. After mixing in the first stage vortex mixing chamber, the first stage mixer output fluid is empty lipid nanoparticles. The size of the empty lipid nanoparticles is determined by the turbulent kinetic energy and mixing time (τ mix The time it takes for the first stage mixer exit fluid to enter the second stage mixer depends on several mixing parameters, such as the time (τ res ) passes. The empty lipid nanoparticles enter the second stage mixer as described above for each of Figures 5, 8, 9, and 10. Nucleic acid is then also introduced into the second stage mixer as described above for each of Figures 5, 8, 9, and 10. Thus, the empty lipid nanoparticles are mixed with the nucleic acid in the second stage mixer. The nucleic acid is incorporated into the empty lipid nanoparticles to form nucleic acid-carrying nanoparticles. The fluid containing the nucleic acid-carrying nanoparticles then exits the second stage mixer through the second stage mixer outlet to the second stage mixer outlet channel. Enlarging the mixer may change wall effects and inlet flow dynamics, but the speed can be adjusted to regain the desired mixing characteristics.

[0057] 11A, 11B, 11C, and 11D show a mixing system 1100 according to an embodiment. In some embodiments, the mixing system 1100 may have multiple single stage mixers or multi-stage mixing systems. In some embodiments, the mixers may have the same or substantially similar characteristics as the mixers described herein with reference to FIGS. 1A-1E, 2, 3A-3B, and / or 4A-4C. In some embodiments, the multi-stage mixing systems may have the same or substantially similar characteristics as the multi-stage mixing systems described herein with reference to FIGS. 5, 6A-6B, 7A-7B, 8, 9A-9B, and / or 10. In this embodiment, inlets 1166, 1167, 1168, and 1169 feed inlet channels 1105, 1110, 1115, and 1120, respectively. The inlet channels 1105, 1110, 1115, 1120 feed the vortex mixing chamber 1150 and exit through the outlet 1155 and outlet channel 1160. In this embodiment, the inlets 1166, 1167, 1168, 1169 are pipettes coupled to a mixer plate 1121. The mixer plate 1121 includes n reactors arranged side-by-side in a d×w configuration in the plane of the mixer plate 1121, where n, d, and w are integers. In the embodiment illustrated in FIG. 11A and FIG. 11B, n=24, d=6, and w=4. In this embodiment, there are four inlets in each vortex mixer, so the number of pipettes used is 96. In some embodiments, the mixing system 1100 can include any single stage mixer as previously shown in FIG. 1A-FIG. 1E. In some embodiments, the mixing system 1100 can include any multi-stage mixing system as shown in FIG. 5. In some embodiments, d and / or w can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more.

[0058] FIG. 12 illustrates a mixing system 1200 with a mixing plate 1221, according to an embodiment. In some embodiments, the mixing plate 1221 may be the same or substantially similar to the mixing plate 1121, as shown in FIG. 11, and may be attached to multiple pipettes (not shown) to create a mixing system the same or substantially similar to the mixing system 1100 previously illustrated with reference to FIG. 11. The mixing plate 1221 may be in a fixed position relative to a conveyor stand 1220. The mixing system 1200 may include multiple product containers 1222. The mixed fluid may be deposited in the product container 1222 after it travels through a system of single or multi-stage vortex mixers in the mixing plate 1221. The product container 1222 may have a number of cavities corresponding to the number of single or multi-stage vortex mixers on the mixing plate 1221. The mixing plate 1221 may dispense the products one by one from each of its single or multi-stage vortex mixers into the product container 1222. Once a single product container 1222A has received a desired amount of product fluid, the flow of fluid into the single product container 1222A can be temporarily stopped while the conveyor stand 1220 moves the subsequent product container 1222B to a position where the subsequent product container 1222B can receive the product. This process can continue for n product containers 1222, where n is an integer. In some embodiments, n can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or more. In some embodiments, the mixing system 1200 can be automated.

[0059] However, in some embodiments, fouling occurs and foulants accumulate in the vortex mixing chamber. This can result in pressure build-up and spikes as the accumulated foulants block the outlet. Foulants can also accumulate at or near the side walls. As mixing time increases, foulants accumulate, causing an increase in the Pressure Differential Index (PDI) and a decrease in mixing efficiency. This further reduces the mixing quality at or near the side walls of the vortex mixing chamber. This is illustrated in Figures 13A-13C. Figure 13A shows foulants accumulated in the vortex mixing chamber 1350 of the vortex mixer 1300. Figure 13B is a graph showing the increase in pressure associated with fouling over time. Figure 13C shows the increase in pressure near the side walls of the vortex mixing chamber as a result of foulants accumulating in both the mid-chamber and the first and / or second walls of the vortex mixing chamber 1350.

[0060] In some such embodiments, the height of the vortex mixing chamber may be the same as the height of the inlets and / or inlet flow channels. This scaling is shown in FIG. 14A. However, it has been found that increasing the height of the vortex mixing chamber reduces fouling and improves mixing quality. Accordingly, FIG. 14B shows an alternative embodiment in which the height of the vortex mixing chamber is increased while other relative dimensions of the vortex mixer 1400 remain the same. Thus, the height of the vortex mixing chamber is greater than the height of the inlets and / or inlet flow channels. In one such embodiment, as shown in FIG. 14B, the sidewall 1453 of the vortex mixing chamber 1450 may extend above the tops of the inlets 1425, 1430, 1435, 1440 and below the bottoms of the inlets 1425, 1430, 1435, 1440. Thus, the distance between the first wall 1451 and the second wall 1452 of the vortex mixing chamber is greater than the height of the inlets 1425, 1430, 1435, 1440. In some embodiments, the inlets 1425, 1430, 1435, 1440 may be centered within the height of the side wall 1453. A comparison of pressure over time for the embodiments of Figures 14A and 14B is shown in the graph of Figure 14C. The baseline pressure decreases and the operating time before pressure rise increases.

[0061] Figures 14D-14F show an exemplary vortex mixer at various scales. Figure 14D shows an exemplary vortex mixer with an outlet / outlet channel diameter of about 0.3 mm. Figure 14E shows an exemplary vortex mixer with an outlet / outlet channel diameter of about 1.0 mm. Figure 14F shows an exemplary vortex mixer with an outlet / outlet channel diameter of about 4.0 mm. All other dimensions are scaled accordingly.

[0062] For example, in a first embodiment, the diameter of the outlet / outlet channel may be about 1.0 mm and the dimensions may be as follows:

[0063] [Table 1]

[0064] The size of the vortex mixer can be scaled up or down. For example, the dimensions can be 0.25x, 0.5x, 0.75x, 1x, 2x, 2.5x, 3x, 4x, 5x, and / or any other scale. Exemplary dimensions are shown in the table below.

[0065] [Table 2]

[0066] By changing the dimensions, the flow rates through the inlet and outlet channels / outlets can be changed proportionally. In an exemplary embodiment, the first fluid flows through the first inlet channel 1405 to the first inlet 1425 and through the third inlet channel 1415 to the third inlet 1435, and the second fluid flows through the second inlet channel 1410 to the second inlet 1430 and through the fourth inlet channel 1420 to the fourth inlet 1440. The first and second fluids may be directed to their respective inlet channels by separate fluid entry lines (not shown) or through a flow divider, as described above. The first and third inlets 1425, 1435 may allow the first fluid to enter the vortex mixing chamber 1450 in a head-on or nearly head-on manner. Similarly, the second and fourth inlets 1430, 1440 may allow the second fluid to enter the vortex mixing chamber 1450 either directly opposite or nearly opposite. Each of the first, second, third, and fourth inlets 1425, 1430, 1435, 1440 may allow the fluid to enter the vortex mixing chamber at exactly or nearly 90 degrees from the other inlets, respectively. As noted above, the inlets 1425, 1430, 1435, 1440 and inlet channels 1405, 1410, 1415, 1420 may be configured tangentially to the vortex mixing chamber 1450, normal to the vortex mixing chamber 1450, or at any angle in between.

[0067] In some embodiments, using the 1x scale above, the flow rate of the first fluid may be 15 ml / min in each of the first and third inlet channels 1405, 1415, and the flow rate of the second fluid may be 45 ml / min in each of the second and fourth inlet channels 1410, 1420. The flow rate through the outlet channel 1460 may be 120 ml / min. These rates may change when scaling the vortex mixer up or down, as described above. So, for example, the flow rates may change as follows:

[0068] [Table 3]

[0069] As discussed above with respect to Figures 14A-14B, increasing the height of the vortex mixing chamber may require an increase in flow rate to maintain the same mixing energy. Figures 15A-15C show mixing in the chamber, with dark blue representing no mixing (or minimal mixing) and green representing full mixing (or near full mixing). Figure 15A shows mixing at a set inlet velocity in a 1x scale vortex mixer, while Figure 15B shows mixing at the same set inlet velocity in a 4x scale vortex mixer. The 1x scale vortex mixer of Figure 15A results in significantly more mixing than the 4x scale vortex mixer of Figure 15B at the same set inlet velocity. Thus, to achieve better mixing in the larger scale vortex mixer, the inlet velocity is increased as shown in Figure 15C. FIG. 15D, along with FIGS. 15A-15C, is a graph showing the mixing time scale (in ms) as a function of inflow velocity (m / s).

[0070] Furthermore, increasing the height of the vortex mixing chamber so that it is greater than the height of the inlet arm and inlet, for example from the embodiment shown in Figure 14A to the embodiment shown in Figure 14B, results in a decrease in the coefficient of variation while maintaining the central mixing pattern. The coefficient of variation (CoV) can be a particular distribution of phases at the outlet and / or outlet flow path,

[0071]

number

[0072] It could be. In the exemplary embodiment, increasing the height of the vortex mixing chamber will decrease the coefficient of variation from 61 to 35. FIG. 15E shows the corresponding changes in the horizontal mid-plane, vertical mid-plane, and first wall of the vortex mixing chamber. The left column of FIG. 15E shows the mass fraction of the first fluid upon mixing for the embodiment previously described in FIG. 14A. The right column of FIG. 15E shows the mass fraction of the first fluid upon mixing for the embodiment previously described with respect to FIG. 14B. In the above exemplary embodiment, FIG. 15E may show the mass fraction of ethanol in the vortex mixer.

[0073] FIG. 16A shows exemplary minimum flow rates and minimum and maximum batch sizes for various exit channel / outlet diameters. Other dimensions of the vortex mixer can be proportionally scaled as appropriate, similar to the graphs above. FIG. 16B shows the resulting nanoparticle diameter (nm) as a function of total flow rate (ml / min) for an exit channel / outlet diameter of 0.3 mm, an exit channel / outlet diameter of 0.5 mm, and an exit channel / outlet diameter of 1.0 mm. FIG. 16C shows the resulting nanoparticle diameter (nm) as a function of inlet velocity (m / s) for an exit channel / outlet diameter of 0.3 mm, an exit channel / outlet diameter of 0.5 mm, and an exit channel / outlet diameter of 1.0 mm. FIG. 16D shows the resulting particle diameter (nm) as a function of inlet velocity (m / s) for an outlet channel / outlet diameter of 1.0 mm, an outlet channel / outlet diameter of 2.0 mm, and an outlet channel / outlet diameter of 4.0 mm.

[0074] Given the data in Figure 16D, a higher inlet velocity is required to achieve the same particle size in a larger scale mixer. That is, a mixer with a 4.0 mm diameter outlet channel / outlet will have a higher inlet velocity than a mixer with a 2.0 mm diameter outlet channel / outlet and a mixer with a 1.0 mm diameter outlet channel / outlet to achieve the same particle size, and the inlet velocity of the 2.0 mm diameter outlet channel / outlet is lower than that of the 4.0 m / s outlet channel / outlet diameter mixer, but is higher than that of the 1.0 m / s outlet channel / outlet diameter mixer. By comparing the velocities required to achieve the particle size, effective velocity adjustments can be applied. Due to the energy loss associated with larger mixers, a 2.0 mm outlet / outlet diameter mixer loses approximately or exactly 10% of the energy compared to a 1.0 mm outlet / outlet diameter mixer, and a 4.0 mm outlet / outlet diameter mixer loses approximately or exactly 30% of the energy compared to a 1.0 mm outlet / outlet diameter mixer. To compensate for this energy loss, an effective velocity adjustment can be applied to the inlet velocity so that an adjusted inlet velocity can be determined. Thus, for a 1.0 mm outlet / outlet diameter mixer, the effective velocity adjustment is 100%, for a 2.0 mm outlet / outlet diameter mixer, the effective velocity adjustment is 90% (compensating for the 10% energy loss), and for a 4.0 mm outlet / outlet diameter mixer, the effective velocity adjustment is 70% (compensating for the 30% energy loss). These values ​​are shown in the table in FIG. 16E.

[0075] Figure 16F shows the plot of Figure 16D after applying the effective velocity adjustment of Figure 16E. As mentioned above, Figure 16F shows particle size (nm) as a function of adjusted inlet velocity (m / s). Figure 16G shows the pressure in the vortex mixer (psi) as a function of adjusted inlet velocity (m / s). This shows that while particle size (nm) can be adjusted by varying the inlet velocity, increasing the inlet velocity results in higher operating pressures.

[0076] FIG. 16H shows the resulting nanoparticle diameter (nm) as a function of turbulent kinetic energy (TKE) (J / kg) for an exit channel / outlet diameter of 0.3 mm, an exit channel / outlet diameter of 0.5 mm, and an exit channel / outlet diameter of 1.0 mm. TKE can be the average kinetic energy per mass associated with turbulent eddies in a flow. FIG. 16I shows the resulting nanoparticle diameter (nm) as a function of minimum mixing time (ms) for an exit channel / outlet diameter of 0.3 mm, an exit channel / outlet diameter of 0.5 mm, and an exit channel / outlet diameter of 1.0 mm. As shown, the diameter is a function of the turbulent kinetic energy and the minimum mixing time (τ mix ) The time to reach a fully mixed state is

[0077]

number

[0078] is defined as follows: The residence time of the fluid in the vortex mixing chamber should be longer than the time scale of micromixing, otherwise the fluid will exit the mixer before it is completely mixed. Therefore, the average residence time of the fluid in the chamber is

[0079]

number

[0080] It has to be. Based on the data of the graphs of FIG. 16H to FIG. 16I, when the turbulent kinetic energy TKE>2 J / kg, the mixing time τ mix As mentioned above, when using larger geometries at a constant velocity, the increase in TKE and τ are required to obtain a perfect turbulent profile in the vortex mixing chamber. mixA reduction in the flow rate may be required. Figure 16J shows the TKE (J / kg) as a function of inlet velocity (m / s) for 0.5 mm, 1.0 mm, 2.0 mm, and 4.0 mm outlet channel / outlet diameters. Figure 16K shows the minimum mixing time (ms) as a function of inlet velocity (m / s) for these same geometries.

[0081] Figure 16L shows the minimum total flow rate (ml / min) to achieve sufficient mixing for various mixer scales (outlet / outlet channel diameter in mm). Figure 16M is a table showing the minimum total flow rate for mixers with 0.3 mm outlet / outlet channel diameter, 0.5 mm outlet / outlet channel diameter, 1.0 mm outlet / outlet channel diameter, 2.0 mm outlet / outlet channel diameter, and 4.0 mm outlet / outlet channel diameter.

[0082] FIG. 16N shows the inlet Reynolds number as a function of inlet velocity (m / s) for an outlet channel / outlet diameter of 0.5 mm, an outlet channel / outlet diameter of 1.0 mm, an outlet channel / outlet diameter of 2.0 mm, and an outlet channel / outlet diameter of 4.0 mm.

[0083] In some embodiments, it has been found that premature mixing of the nucleic acid and precipitation occurs when the nucleic acid interacts with ethanol. Premature mixing of the nucleic acid affects the efficient assembly of lipid nanoparticles, and precipitation leads to fouling. Therefore, instead of forming lipid nanoparticles with nucleic acid encased therein in a single step as described in the above exemplary embodiment, a two-stage vortex mixer can be used. The two-stage vortex mixer may comprise two mixers in series, i.e., a first stage vortex mixer and a second stage vortex mixer. In the first stage vortex mixer, lipids in ethanol (i.e., lipid master mix) can be mixed with an acidic buffer to form empty nanoparticles, and in the second stage vortex mixer, the empty nanoparticles formed in the first stage vortex mixer can be mixed with nucleic acid to form nucleic acid-carrying nanoparticles. In this way, the formation of empty nanoparticles and the addition of nucleic acid to form nucleic acid-carrying nanoparticles are separated in time. Therefore, the empty nanoparticles are fully formed before the nucleic acid is introduced. Since the nucleic acid is not exposed to an unemulsified buffer, the degradation of the nucleic acid due to exposure to an acidified buffer is avoided. Instead, empty lipid nanoparticles are formed, and the nucleic acid is introduced into the second stage vortex mixer, where the nucleic acid is incorporated into the empty lipid nanoparticles by hydrophobic and / or charge interactions. This results in better encapsulation of the nucleic acid in the lipid nanoparticles, thereby resulting in more integrated particles.

[0084] FIG. 17A shows a graph of pressure change over time (min) from a baseline pressure (psi). The green plot shows the pressure change for the single stage mixer while the orange plot line shows the pressure change for the dual stage mixer shown in FIG. 10. FIG. 17B shows a graph of pressure change over time (min) from a baseline pressure (psi). FIG. 17B shows the same plot as FIG. 17A, with the green plot line showing the pressure change for the single stage mixer and the orange plot line showing the pressure change for the dual stage mixer of FIG. 10, but with the pressure change for the dual stage mixer of FIG. 5 shown in red. This shows that the embodiment of FIG. 5 has significantly reduced pressure fluctuations and pressure spikes compared to the single stage mixer and the dual stage mixer of FIG. 10. This is at least in part because the embodiment of FIG. 5 produces much less fouling than the single stage mixer and the dual stage mixer of FIG. 10.

[0085] Figure 17C shows the second stage mixer 1002 after a sample test run for the embodiment of Figure 10. Figure 17D shows the second stage mixer 502 after a sample test run for the embodiment of Figure 5. Figure 17D shows no or minimal precipitant, meaning no or minimal fouling occurred, while Figure 17C shows a buildup of precipitant, meaning fouling occurred, explaining the pressure rise and pressure spikes shown in the green and orange plots in Figures 17A-B.

[0086] 18A shows fluid path lines in an exemplary vortex mixer that receives two fluids by inlet / inlet channels along a sidewall 1853 of a vortex mixing chamber 1850. A first fluid enters the vortex mixing chamber 1850 through a first inlet channel 1805 / inlet 1825 and a third inlet channel 1815 / inlet 1835, and a second fluid enters the vortex mixing chamber 1850 through a second inlet channel 1810 / inlet 1830 and a fourth inlet channel 1820 / inlet 1840. In FIG. 18A, the first fluid is shown in blue as it enters the vortex mixing chamber 1850 through the first inlet channel 1805 / inlet 1825, and the second fluid is shown in red after it enters the vortex mixing chamber 1850 through the second inlet channel 1810 / inlet 1830. For ease of viewing, the colors associated with the third and fourth inlet channels / inlets are not shown. When the blue and red fluids are fully mixed, the fluid path lines are shown in yellow. In this embodiment, the first fluid is concentrated along the sidewall past the first inlet 1825, and the second fluid is concentrated along the sidewall past the second inlet 1830, as shown in FIG. 18A. In this manner, mixing begins along the sidewalls 1853 of the vortex mixing chamber 1850 and the thoroughly mixed fluids circulate around the vortex mixing chamber 1850 toward the center of the chamber until the mixed fluids reach the outlet and exit through the outlet channel 1860. This configuration can result in severe fouling as most of the mixing occurs at the sidewalls 1850 and the first fluid becomes supersaturated after the first and third inlets 1825, 1835 and the second fluid becomes supersaturated after the second and fourth inlets 1830, 1840.

[0087] 18B illustrates fluid lines in an alternative configuration of a vortex mixer, such as the configuration shown in the second stage mixer 502 of FIG. 5 (and described above with respect to FIGS. 17B and 17D ), where a first fluid may enter the vortex mixing chamber 1880 through at least a first inlet channel 1875 / inlet 1885 and a second inlet channel 1877 / inlet 1886, and a second fluid may enter the vortex mixing chamber 1880 through a third inlet channel 1878 / inlet 1888. The first and second inlets 1885, 1886 may be configured along a side wall 1883 of the vortex mixing chamber 1880, while the third inlet 1888 may be configured in a first wall 1881 of the vortex mixing chamber 1880. A first wall 1881 of the vortex mixing chamber 1880 may be configured opposite a second wall 1882 of the vortex mixing chamber 1880, where the first wall 1881 and the second wall 1882 are parallel (or nearly parallel) to each other and connected via a side wall 1883. In some embodiments, a third inlet 1888 may be configured at or near a radial center of the first wall 1881 and may face an outlet 1889 configured at or near a radial center of the second wall 1882. The outlet 1889 may be connected to an outlet channel 1890.

[0088] In FIG. 18B, the blue fluid line represents the second fluid entering the vortex mixing chamber 1880 from the third inlet channel 1878 / inlet 1888. The second fluid mixes with the first fluid (not shown) swirling through the vortex mixing chamber 1880. The mixing occurs at or near the center of the vortex mixing chamber 1880. Some, most, or all of the mixing occurs within the vortex mixing chamber 1880 before the mixed fluid, shown in yellow, exits the vortex mixing chamber 1880 through outlet 1889 to the outlet channel 1890. In some embodiments, all or nearly all of the mixing occurs within the vortex mixing chamber 1880 before the mixed fluid exits the vortex mixing chamber 1880 through outlet 1889 to the outlet channel 1890. In some embodiments, some mixing may occur within the vortex mixing chamber 1880 and mixing may continue as the fluid swirls past the outlet 1889 and into the outlet channel 1890.

[0089] In the embodiment of Figure 18B, mixing occurs at or near the center of the vortex mixing chamber 1880. In this configuration, mixing occurs away from the walls of the vortex mixing chamber 1880, avoiding the oversaturation of the interacting fluids discussed in Figure 18A, resulting in reduced fouling and reduced mixing times.

[0090] 19A-19B show the mixing ratio as a function of time (s). The mixing ratio may correspond to the ratio of a first component contained in a first fluid to be mixed in the vortex mixer to a second component contained in a second fluid to be mixed in the vortex mixer. For example, when mixing lipids and nucleic acids, a local N:P ratio can be used, where N represents the nitrogen group in the lipid and P represents the phosphorus group in the nucleic acid. FIG. 19A shows the mixing ratio as a function of time (s) for the embodiment of FIG. 18A, and FIG. 19B shows the mixing ratio as a function of time (s) for the embodiment of FIG. 18B. As a result, equilibrium (e.g., fully mixed ratio) is achieved much faster in the mixer of FIG. 18B than in the mixer of FIG. 18A. In the embodiment of Figures 18B and 19B, the N:P ratio reaches equilibrium at about 0.002 seconds, whereas in the embodiment of Figures 18A and 19A, the N:P ratio does not reach equilibrium until about 0.025 seconds.

[0091] It should be noted that although the above exemplary embodiments refer to forming nucleic acid-containing lipid nanoparticles, the lipid nanoparticles can also encapsulate other nucleic acids, proteins, and the like.

[0092] Each of the embodiments of the vortex mixer(s) described herein can be formed from a number of materials, including but not limited to stainless steel, LFEM, acrylic, PEEK, 3D printed media, and the like.

[0093] Any and all references presented in this application to publications or other documents, including but not limited to patents, patent applications, articles, web pages, books, and the like, are incorporated herein by reference in their entirety.

[0094] definition As used herein, the term "about" or "approximately" generally means ±10% of the stated value, e.g., about 90 degrees includes 81 degrees to 99 degrees, and about 1,000 μm includes 900 μm to 1,100 μm. In some embodiments, "about" or "approximately" generally means ±9%, ±8%, ±7%, ±6%, ±5%, ±4%, ±3%, ±2%, or ±1% of the stated value. In some embodiments, when "about" or "approximately" refers to an angle measurement, these terms generally mean ±10 degrees, ±9 degrees, ±8 degrees, ±7 degrees, ±6 degrees, ±5 degrees, ±4 degrees, ±3 degrees, ±2 degrees, or ±1 degree of the stated value. In some embodiments, when "about" or "approximately" refers to a distance, these terms generally mean ±10 mm, ±9 mm, ±8 mm, ±7 mm, ±6 mm, ±5 mm, ±4 mm, ±3 mm, ±2 mm, ±1 mm, ±900 μm, ±800 μm, ±700 μm, ±600 μm, ±500 μm, ±400 μm, ±300 μm, ±200 μm, ±100 μm, ±90 μm, ±80 μm, ±70 μm, ±60 μm, ±50 μm, ±40 μm, ±30 μm, ±20 μm, or ±10 μm of the stated value.

[0095] nucleic acid In some embodiments, the nucleic acid is a polynucleotide (e.g., ribonucleic acid or deoxyribonucleic acid). In its broadest sense, the term "polynucleotide" includes any compound and / or substance that is or can be incorporated into an oligonucleotide chain. Exemplary polynucleotides for use in accordance with the present disclosure include, but are not limited to, one or more of deoxyribonucleic acid (DNA), ribonucleic acid (RNA), including messenger RNA (mRNA), hybrids thereof, RNAi inducers, RNAi agents, siRNA, shRNA, miRNA, antisense RNA, ribozymes, catalytic DNA, RNA that induces triple helix formation, aptamers, vectors, and the like. In some embodiments, the nucleic acid or polynucleotide is RNA. The RNA may be selected from the group consisting of, but is not limited to, a shortmer, an antagomir, an antisense, a ribozyme, a small interfering RNA (siRNA), an asymmetric interfering RNA (aiRNA), a microRNA (miRNA), a dicer substrate RNA (dsRNA), a small hairpin RNA (shRNA), a transfer RNA (tRNA), a messenger RNA (mRNA), and mixtures thereof. In some embodiments, the RNA is an mRNA.

[0096] In some embodiments, the nucleic acid or polynucleotide is mRNA.The mRNA can code for any polypeptide of interest, including any natural or non-natural or modified polypeptide.The polypeptide coded by the mRNA can be of any size and have any secondary structure or activity.In some embodiments, the polypeptide coded by the mRNA can have therapeutic effect when expressed in cells.

[0097] In some embodiments, the nucleic acid or polynucleotide is siRNA.The siRNA can be capable of selectively knocking down or downregulating the expression of a gene of interest.For example, the siRNA can be selected to silence a gene associated with a particular disease, disorder, or pathology when a lipid-containing composition comprising the siRNA is administered to a subject in need.The siRNA can comprise a sequence that is complementary to the mRNA sequence that codes for the gene or protein of interest.In some embodiments, the siRNA can be an immunomodulatory siRNA.

[0098] In some embodiments, the nucleic acid or polynucleotide is sgRNA and / or cas9 mRNA. sgRNA and / or cas9 mRNA can be used as gene editing tools. For example, sgRNA-cas9 complex can affect the mRNA translation of cellular genes.

[0099] In some embodiments, the nucleic acid or polynucleotide is shRNA or its encoding vector or plasmid.shRNA can be produced inside target cell when appropriate construct is delivered to nucleus.The construct and mechanism related to shRNA are well known in the art.

[0100] Nucleic acids and polynucleotides useful in the present disclosure typically include a first region of linked nucleosides that encodes a polypeptide of interest (e.g., a coding region), a first flanking region located at the 5' end of the first region (e.g., a 5'-UTR), a second flanking region located at the 3' end of the first region (e.g., a 3'-UTR), at least one 5'-cap region, and a 3'-stabilizing region. In some embodiments, the nucleic acid or polynucleotide further includes a poly-A region or a Kozak sequence (e.g., in the 5'-UTR). In some embodiments, the polynucleotide may contain one or more intron nucleotide sequences that can be excised from the polynucleotide. In some embodiments, the polynucleotide or nucleic acid (e.g., an mRNA) may include a 5' cap structure, a chain terminating nucleotide, a stem loop, a polyA sequence, and / or a polyadenylation signal. Any one of the regions of the nucleic acid may include one or more modified components (e.g., modified nucleosides). For example, the 3'-stabilization region may contain modified nucleosides, such as L-nucleosides, reverse thymidines, or 2'-O-methyl nucleosides, and / or the coding region, 5'-UTR, 3'-UTR, or cap region may include modified nucleosides, such as 5-substituted uridines (e.g., 5-methoxyuridine), 1-substituted pseudouridines (e.g., 1-methyl-pseudouridine or 1-ethyl-pseudouridine), and / or 5-substituted cytidines (e.g., 5-methyl-cytidine).

[0101] In general, the shortest length of a polynucleotide may be the length of the polynucleotide sequence sufficient to encode a dipeptide. In some embodiments, the length of the polynucleotide sequence is sufficient to encode a tripeptide. In some embodiments, the length of the polynucleotide sequence is sufficient to encode a tetrapeptide. In some embodiments, the length of the polynucleotide sequence is sufficient to encode a pentapeptide. In some embodiments, the length of the polynucleotide sequence is sufficient to encode a hexapeptide. In some embodiments, the length of the polynucleotide sequence is sufficient to encode a heptapeptide. In some embodiments, the length of the polynucleotide sequence is sufficient to encode an octapeptide. In some embodiments, the length of the polynucleotide sequence is sufficient to encode a nonapeptide. In some embodiments, the length of the polynucleotide sequence is sufficient to encode a decapeptide.

[0102] Examples of dipeptides that the modified polynucleotide sequence can encode include, but are not limited to, carnosine and anserine. In some embodiments, a polynucleotide is more than 30 nucleotides in length, more than 35 nucleotides in length, at least 40 nucleotides, at least 45 nucleotides, at least 55 nucleotides, at least 50 nucleotides, at least 60 nucleotides, at least 80 nucleotides, at least 90 nucleotides, at least 100 nucleotides, at least 120 nucleotides, at least 140 nucleotides, at least 160 nucleotides, at least 180 nucleotides, at least 200 nucleotides, at least 250 nucleotides, at least 300 nucleotides, at least 350 nucleotides, at least 400 nucleotides, at least 450 nucleotides, nucleotides, at least 500 nucleotides, at least 600 nucleotides, at least 700 nucleotides, at least 800 nucleotides, at least 900 nucleotides, at least 1000 nucleotides, at least 1100 nucleotides, at least 1200 nucleotides, at least 1300 nucleotides, at least 1400 nucleotides, at least 1500 nucleotides, at least 1600 nucleotides, at least 1800 nucleotides, at least 2000 nucleotides, at least 2500 nucleotides, at least 3000 nucleotides, at least 4000 nucleotides, at least 5000 nucleotides, or more than 5000 nucleotides.

[0103] Nucleic acids and polynucleotides may contain one or more naturally occurring components that contain any of the standard nucleotides A (adenosine), G (guanosine), C (cytosine), U (uridine), or T (thymidine). In some embodiments, all or substantially all of the nucleotides comprising (a) the 5'-UTR, (b) the open reading frame (ORF), (c) the 3'-UTR, (d) the poly-A tail, and any combination of (a, b, c, or d above) contain the naturally occurring standard nucleotides A (adenosine), G (guanosine), C (cytosine), U (uridine), or T (thymidine).

[0104] Nucleic acids and polynucleotides may contain one or more alternative components described herein that confer useful properties, including improved stability and / or substantially no induction of an innate immune response in cells into which the polynucleotide is introduced. For example, the alternative polynucleotides or nucleic acids exhibit reduced degradation in cells into which the polynucleotide or nucleic acid is introduced, compared to the corresponding unmodified polynucleotide or nucleic acid. These alternative species can improve the efficiency of protein production, intracellular retention of the polynucleotide, and / or viability of the contacted cells, as well as have reduced immunogenicity.

[0105] Polynucleotides and nucleic acids can be natural or non-natural. Polynucleotides and nucleic acids can include one or more modifications (e.g., modified or alternative nucleobases, nucleosides, nucleotides, or combinations thereof. Nucleic acids and polynucleotides can include any useful modifications or alterations, such as those to the nucleobases, sugars, or internucleoside linkages (e.g., linking phosphate / phosphodiester linkages / phosphodiester backbones). In some embodiments, the modifications (e.g., one or more modifications) are present in each of the nucleobases, sugars, and internucleoside linkages. Modifications according to the present disclosure can be modifications of ribonucleic acid (RNA) to deoxyribonucleic acid (DNA) (e.g., replacement of 2'-OH of a ribofuranosyl ring with 2'-H), threose nucleic acid (TNA), glycol nucleic acid (GNA), peptide nucleic acid (PNA), locked nucleic acid (LNA), or hybrids thereof. Further modifications are described herein.

[0106] Polynucleotides and nucleic acids may be uniformly modified or not uniformly modified along the entire length of the molecule. For example, one or more or all types of nucleotides (e.g., purines or pyrimidines, or one or more or all of A, G, U, C) may be uniformly modified or not uniformly modified in a polynucleotide or nucleic acid or in a given sequence region thereof. In some embodiments, all nucleotides X in a polynucleotide (or in a given sequence region thereof) are modified, where X can be any one of the nucleotides A, G, U, C, or any one of the combinations A+G, A+U, A+C, G+U, G+C, U+C, A+G+U, A+G+C, G+U+C, or A+G+C.

[0107] Different sugar modifications and / or internucleoside linkages (e.g., backbone structures) can be present at various positions of a polynucleotide. It will be understood by those skilled in the art that the nucleotide analogue or other modification(s) can be located at any position(s) of a polynucleotide such that the function of the polynucleotide is not substantially diminished. Modifications can also be 5'- or 3'-terminal modifications. In some embodiments, the polynucleotide comprises a modification at the 3'-terminus. A polynucleotide may contain from about 1% to about 100% alternative nucleotides (either relative to the total nucleotide content or relative to one or more types of nucleotides, i.e., any one or more of A, G, U or C), or any percentage in between (e.g., 1%-20%, 1%-25%, 1%-50%, 1%-60%, 1%-70%, 1%-80%, 1%-90%, 1%-95%, 10%-20%, 10%-25%, 10%-50%, 10%-60%, 10%-70%, 10%-80%, 10%-90%, 10% to 95%, 10% to 100%, 20% to 25%, 20% to 50%, 20% to 60%, 20% to 70%, 20% to 80%, 20% to 90%, 20% to 95%, 20% to 100%, 50% to 60%, 50% to 70%, 50% to 80%, 50% to 90%, 50% to 95%, 50% to 100%, 70% to 80%, 70% to 90%, 70% to 95%, 70% to 100%, 80% to 90%, 80% to 95%, 80% to 100%, 90% to 95%, 90% to 100%, and 95% to 100%). It will be understood that the occurrence of standard nucleotides (eg, A, G, U, or C) make up any remaining percentages.

[0108] A polynucleotide may contain a minimum of 0% and a maximum of 100% alternative nucleotides, or any percentage in between, such as at least 5% alternative nucleotides, at least 10% modified nucleotides, at least 25% alternative nucleotides, at least 50% alternative nucleotides, at least 80% alternative nucleotides, or at least 90% alternative nucleotides. For example, a polynucleotide may contain alternative pyrimidines, such as alternative uracils or cytosines. In some embodiments, at least 5%, at least 10%, at least 25%, at least 50%, at least 80%, at least 90% or 100% of the uracils in a polynucleotide are replaced with modified uracils (e.g., 5-substituted uracils). The alternative uracils may be replaced with a compound having a single unique structure, or may be replaced with multiple compounds having different structures (e.g., 2, 3, 4 or more unique structures). In some embodiments, at least 5%, at least 10%, at least 25%, at least 50%, at least 80%, at least 90% or 100% of the cytosines in a polynucleotide are substituted with alternative cytosines (e.g., 5-substituted cytosines). The alternative cytosines may be substituted with a compound having a single unique structure, or may be substituted with multiple compounds having different structures (e.g., 2, 3, 4 or more unique structures).

[0109] In some embodiments, the nucleic acid does not substantially induce an innate immune response in a cell into which the polynucleotide (e.g., mRNA) has been introduced, the innate immune response being characterized by: 1) increased expression of pro-inflammatory cytokines, 2) activation of intracellular PRRs (e.g., RIG-I, MDA5, etc.), and / or 3) termination or reduction of protein translation.

[0110] The nucleic acid may optionally include other agents (e.g., RNAi-inducing agents, RNAi agents, siRNAs, shRNAs, miRNAs, antisense RNAs, ribozymes, catalytic DNAs, tRNAs, RNAs that induce triple helix formation, aptamers, vectors). In some embodiments, the nucleic acid may include one or more messenger RNAs (mRNAs) with one or more alternative nucleosides or nucleotides (i.e., alternative mRNA molecules).

[0111] In some embodiments, the nucleic acid (e.g., mRNA) may be prepared using methods described in WO2002 / 098443, WO2003 / 051401, WO2008 / 052770, WO2009127230, WO2006122828, WO2008 / 083949, WO2010088927, WO2010 / 037539, WO2004 / 004743, WO2005 / 016376, WO2006 / 024518, WO2007 / 024520, WO2009 / 024539, WO2010 ... 007 / 095976, WO2008 / 014979, WO2008 / 077592, WO2009 / 030481, WO2009 / 095226, WO2011069586, WO20110266 41, WO2011 / 144358, WO2012019780, WO2012013326, WO2012089338, WO2012113513, WO2012116811, WO2012116 810, WO2013113502, WO2013113501, WO2013113736, WO2013143698, WO2013143699, WO2013143700, WO2013 / 1 20626, WO2013120627, WO2013120628, WO2013120629, WO2013174409, WO2014127917, WO2015 / 024669, WO2015 / 024668, WO2015 / 024667, WO2015 / 024665, WO2015 / 024666, WO2015 / 024664, WO2015101415, WO2015101414, WO2015024667, WO2015062738, WO2015101416 (all of which are incorporated by reference herein).

[0112] Nucleobase substitutes Alternative nucleosides and nucleotides may include alternative nucleobases. The nucleobases of nucleic acids are organic bases, such as purines or pyrimidines or derivatives thereof. The nucleobases may be standard bases (e.g., adenine, guanine, uracil, thymine, and cytosine). These nucleobases may be modified or completely replaced to provide polynucleotide molecules with improved properties, such as improved stability, such as resistance to nucleases. Non-standard or modified bases may include one or more substitutions or modifications, including, for example, but not limited to, alkyl, aryl, halo, oxo, hydroxyl, alkyloxy, and / or thio substitutions; one or more fused or open rings; oxidation; and / or reduction.

[0113] Alternative nucleotide base pairing encompasses base pairs formed between alternative nucleotides, including canonical adenine-thymine, adenine-uracil, or guanine-cytosine base pairs, as well as nucleotides and / or non-standard or alternative bases, where the configuration of hydrogen bond donors and hydrogen bond acceptors allows hydrogen bonding between the non-standard and standard bases or between two complementary non-standard base structures. One example of such non-standard base pairing is base pairing between the alternative nucleotide inosine and adenine, cytosine, or uracil.

[0114] In some embodiments, the alternative nucleoside or nucleotide is uridine. In some embodiments, the alternative uridine is 1-methylpseudouridine (1mψ). In some embodiments, 1-methylpseudouridine (1mψ) has the structure

[0115] [ka]

[0116] Includes. Polynucleotides may contain from about 1% to about 100% 1-methylpseudouridine (1mψ) (relative to the total nucleotide content or to one or more types of nucleotides, i.e., any one or more of A, G, U or C), or any percentage in between (e.g., 1%-20%, 1%-25%, 1%-50%, 1%-60%, 1%-70%, 1%-80%, 1%-90%, 1%-95%, 10%-20%, 10%-25%, 10%-50%, 10%-60%, 10%-70%, 10%-80%, 10%-95%, 10%-10 ... 90%, 10% to 95%, 10% to 100%, 20% to 25%, 20% to 50%, 20% to 60%, 20% to 70%, 20% to 80%, 20% to 90%, 20% to 95%, 20% to 100%, 50% to 60%, 50% to 70%, 50% to 80%, 50% to 90%, 50% to 95%, 50% to 100%, 70% to 80%, 70% to 90%, 70% to 95%, 70% to 100%, 80% to 90%, 80% to 95%, 80% to 100%, 90% to 95%, 90% to 100%, and 95% to 100%). It will be understood that the occurrence of standard nucleotides (eg, A, G, U, or C) make up any remaining percentages.

[0117] In some embodiments, uridine is replaced with 1-methylpseudouridine (1mψ). In some embodiments, 1% of the uridine is replaced with 1-methylpseudouridine (1mψ). In some embodiments, 5% of the uridine is replaced with 1-methylpseudouridine (1mψ). In some embodiments, 10% of the uridine is replaced with 1-methylpseudouridine (1mψ). In some embodiments, 15% of the uridine is replaced with 1-methylpseudouridine (1mψ). In some embodiments, 20% of the uridine is replaced with 1-methylpseudouridine (1mψ). In some embodiments, 25% of the uridine is replaced with 1-methylpseudouridine (1mψ). In some embodiments, 30% of the uridine is replaced with 1-methylpseudouridine (1mψ). In some embodiments, 35% of the uridine is replaced with 1-methylpseudouridine (1mψ). In some embodiments, 40% of the uridines are replaced with 1-methylpseudouridine (1mψ). In some embodiments, 45% of the uridines are replaced with 1-methylpseudouridine (1mψ). In some embodiments, 50% of the uridines are replaced with 1-methylpseudouridine (1mψ). In some embodiments, 55% of the uridines are replaced with 1-methylpseudouridine (1mψ). In some embodiments, 60% of the uridines are replaced with 1-methylpseudouridine (1mψ). In some embodiments, 65% of the uridines are replaced with 1-methylpseudouridine (1mψ). In some embodiments, 70% of the uridines are replaced with 1-methylpseudouridine (1mψ). In some embodiments, 75% of the uridines are replaced with 1-methylpseudouridine (1mψ). In some embodiments, 80% of the uridines are replaced with 1-methylpseudouridine (1mψ). In some embodiments, 85% of the uridines are replaced with 1-methylpseudouridine (1mψ). In some embodiments, 90% of the uridines are replaced with 1-methylpseudouridine (1mψ).In some embodiments, 95% of the uridines are replaced with 1-methylpseudouridine (1mψ). In some embodiments, 100% of the uridines are replaced with 1-methylpseudouridine (1mψ).

[0118] The term "polynucleotide," in its broadest sense, includes any compound and / or substance that is or can be incorporated into an oligonucleotide chain having a uridine to 1-methylpseudouridine (1mψ) base modification.

[0119] In some embodiments, the nucleic acid or polynucleotide is an mRNA with uridine to 1-methylpseudouridine (1mψ) base modifications. In some embodiments, the polynucleotide is greater than 30 nucleotides in length with a uridine to 1-methylpseudouridine (1mψ) base modification. In some embodiments, the polynucleotide molecule is greater than 35 nucleotides in length with a uridine to 1-methylpseudouridine (1mψ) base modification. In some embodiments, the length is at least 40 nucleotides with a uridine to 1-methylpseudouridine (1mψ) base modification. In some embodiments, the length is at least 45 nucleotides with a uridine to 1-methylpseudouridine (1mψ) base modification. In some embodiments, the length is at least 55 nucleotides with a uridine to 1-methylpseudouridine (1mψ) base modification. In some embodiments, the length is at least 50 nucleotides with a uridine to 1-methylpseudouridine (1mψ) base modification. In some embodiments, the length is at least 60 nucleotides with a uridine to 1-methylpseudouridine (1mψ) base modification. In some embodiments, the length is at least 80 nucleotides with a uridine to 1-methylpseudouridine (1mψ) base modification. In some embodiments, the length is at least 90 nucleotides with a uridine to 1-methylpseudouridine (1mψ) base modification. In some embodiments, the length is at least 100 nucleotides with a uridine to 1-methylpseudouridine (1mψ) base modification. In some embodiments, the length is at least 120 nucleotides with a uridine to 1-methylpseudouridine (1mψ) base modification. In some embodiments, the length is at least 140 nucleotides with a uridine to 1-methylpseudouridine (1mψ) base modification. In some embodiments, the length is at least 160 nucleotides with a uridine to 1-methylpseudouridine (1mψ) base modification. In some embodiments, the length is at least 180 nucleotides with a uridine to 1-methylpseudouridine (1mψ) base modification.In some embodiments, the length is at least 200 nucleotides with a uridine to 1-methylpseudouridine (1mψ) base modification. In some embodiments, the length is at least 250 nucleotides with a uridine to 1-methylpseudouridine (1mψ) base modification. In some embodiments, the length is at least 300 nucleotides with a uridine to 1-methylpseudouridine (1mψ) base modification. In some embodiments, the length is at least 350 nucleotides with a uridine to 1-methylpseudouridine (1mψ) base modification. In some embodiments, the length is at least 400 nucleotides with a uridine to 1-methylpseudouridine (1mψ) base modification. In some embodiments, the length is at least 450 nucleotides with a uridine to 1-methylpseudouridine (1mψ) base modification. In some embodiments, the length is at least 500 nucleotides with a uridine to 1-methylpseudouridine (1mψ) base modification. In some embodiments, the length is at least 600 nucleotides with a uridine to 1-methylpseudouridine (1mψ) base modification. In some embodiments, the length is at least 700 nucleotides with a uridine to 1-methylpseudouridine (1mψ) base modification. In some embodiments, the length is at least 800 nucleotides with a uridine to 1-methylpseudouridine (1mψ) base modification. In some embodiments, the length is at least 900 nucleotides with a uridine to 1-methylpseudouridine (1mψ) base modification. In some embodiments, the length is at least 1000 nucleotides with a uridine to 1-methylpseudouridine (1mψ) base modification. In some embodiments, the length is at least 1100 nucleotides with a uridine to 1-methylpseudouridine (1mψ) base modification. In some embodiments, the length is at least 1200 nucleotides with a uridine to 1-methylpseudouridine (1mψ) base modification.In some embodiments, the length is at least 1300 nucleotides with a uridine to 1-methylpseudouridine (1mψ) base modification. In some embodiments, the length is at least 1400 nucleotides with a uridine to 1-methylpseudouridine (1mψ) base modification. In some embodiments, the length is at least 1500 nucleotides with a uridine to 1-methylpseudouridine (1mψ) base modification. In some embodiments, the length is at least 1600 nucleotides with a uridine to 1-methylpseudouridine (1mψ) base modification. In some embodiments, the length is at least 1800 nucleotides with a uridine to 1-methylpseudouridine (1mψ) base modification. In some embodiments, the length is at least 2000 nucleotides with a uridine to 1-methylpseudouridine (1mψ) base modification. In some embodiments, the length is at least 2500 nucleotides with a uridine to 1-methylpseudouridine (1mψ) base modification. In some embodiments, the length is at least 3000 nucleotides with uridine to 1-methylpseudouridine (1mψ) base modifications. In some embodiments, the length is at least 4000 nucleotides with uridine to 1-methylpseudouridine (1mψ) base modifications. In some embodiments, the length is at least 5000 nucleotides or greater with uridine to 1-methylpseudouridine (1mψ) base modifications.

[0120] A polynucleotide may contain a minimum of zero and a maximum of 100% uridine to 1-methylpseudouridine (1mψ) base modifications, or any percentage value in between, e.g., at least 5% uridine to 1-methylpseudouridine (1mψ) base modifications, at least 10% uridine to 1-methylpseudouridine (1mψ) base modifications, at least 25% uridine to 1-methylpseudouridine (1mψ) base modifications, at least 50% uridine to 1-methylpseudouridine (1mψ) base modifications, at least 80% uridine to 1-methylpseudouridine (1mψ) base modifications, at least 90% uridine to 1-methylpseudouridine (1mψ) base modifications. The alternative uracils may be replaced with a compound having a single unique structure, or may be replaced with multiple compounds having different structures (e.g., 2, 3, 4 or more unique structures). In some embodiments, at least 5%, at least 10%, at least 25%, at least 50%, at least 80%, at least 90% or 100% of the cytosines in a polynucleotide are substituted with alternative cytosines (e.g., 5-substituted cytosines). The alternative cytosines may be substituted with a compound having a single unique structure, or may be substituted with multiple compounds having different structures (e.g., 2, 3, 4 or more unique structures).

[0121] In some embodiments, the nucleobase is a substituted uracil. Exemplary nucleobases and nucleosides having a substituted uracil include pseudouridine (ψ), pyridin-4-one ribonucleoside, 5-aza-uracil, 6-aza-uracil, 2-thio-5-aza-uracil, 2-thio-uracil (s 2 U), 4-thio-uracil (s 4 U), 4-thio-pseudouridine, 2-thio-pseudouridine, 5-hydroxy-uracil (ho 5 U), 5-aminoallyl-uracil, 5-halo-uracil (e.g., 5-iodo-uracil or 5-bromo-uracil), 3-methyl-uracil (m 3 U), 5-methoxy-uracil (mo 5 U), uracil 5-oxyacetic acid (cmo5 U), uracil 5-oxyacetic acid methyl ester (mcmo 5 U), 5-carboxymethyl-uracil (cm 5 U), 1-carboxymethyl-pseudouridine, 5-carboxyhydroxymethyl-uracil (chm 5 U), 5-carboxyhydroxymethyl-uracil methyl ester (mchm 5 U), 5-methoxycarbonylmethyl-uracil (mcm 5 U), 5-methoxycarbonylmethyl-2-thio-uracil (mcm 5 s 2 U), 5-aminomethyl-2-thio-uracil (nm 5 s 2 U), 5-methylaminomethyl-uracil (mnm 5 U), 5-methylaminomethyl-2-thio-uracil (mnm 5 s 2 U), 5-methylaminomethyl-2-seleno-uracil (mnm 5 se 2 U), 5-carbamoylmethyl-uracil (ncm 5 U), 5-carboxymethylaminomethyl-uracil (cmnm 5 U), 5-carboxymethylaminomethyl-2-thio-uracil (cmnm 5 s 2 U), 5-propynyl-uracil, 1-propynyl-pseudouracil, 5-taurinomethyl-uracil (τm 5 U), 1-taurinomethyl-pseudouridine, 5-taurinomethyl-2-thio-uracil (τm 5 s 2 U), 1-taurinomethyl-4-thio-pseudouridine, 5-methyl-uracil (m 5 U, i.e., having the nucleobase deoxythymine), 1-methyl-pseudouridine (m 1 ψ), 5-methyl-2-thio-uracil (m 5 s 2 U), 1-methyl-4-thio-pseudouridine (m 1 s 4ψ), 4-thio-1-methyl-pseudouridine, 3-methyl-pseudouridine (m 3 ψ), 2-thio-1-methyl-pseudouridine, 1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-1-deaza-pseudouridine, dihydrouracil (D), dihydropseudouridine, 5,6-dihydrouracil, 5-methyl-dihydrouracil (m 5 D), 2-thio-dihydrouracil, 2-thio-dihydropseudouridine, 2-methoxy-uracil, 2-methoxy-4-thio-uracil, 4-methoxy-pseudouridine, 4-methoxy-2-thio-pseudouridine, N1-methyl-pseudouridine, 3-(3-amino-3-carboxypropyl)uracil (acp 3 U), 1-methyl-3-(3-amino-3-carboxypropyl)pseudouridine (acp 3 ψ), 5-(isopentenylaminomethyl)uracil (inm 5 U), 5-(isopentenylaminomethyl)-2-thio-uracil (inm 5 s 2 U), 5,2'-O-dimethyl-uridine (m 5 Um), 2-thio-2'-O_methyl-uridine (s 2 Um), 5-methoxycarbonylmethyl-2'-O-methyl-uridine (mcm 5 Um), 5-carbamoylmethyl-2'-O-methyl-uridine (ncm 5 Um), 5-carboxymethylaminomethyl-2'-O-methyl-uridine (cmnm 5 Um), 3,2'-O-dimethyl-uridine (m 3 Um), and 5-(isopentenylaminomethyl)-2'-O-methyl-uridine (inm 5 Um), 1-thio-uracil, deoxythymidine, 5-(2-carbomethoxyvinyl)-uracil, 5-(carbamoylhydroxymethyl)-uracil, 5-carbamoylmethyl-2-thio-uracil, 5-carboxymethyl-2-thio-uracil, 5-cyanomethyl-uracil, 5-methoxy-2-thio-uracil, and 5-[3-(1-E-propenylamino)]uracil.

[0122] In some embodiments, the nucleobase is an alternative cytosine. Exemplary nucleobases and nucleosides having an alternative cytosine include 5-aza-cytosine, 6-aza-cytosine, pseudoisocytidine, 3-methyl-cytosine (m3C), N4-acetyl-cytosine (ac4C), 5-formyl-cytosine (f5C), N4-methyl-cytosine (m4C), 5-methyl-cytosine (m5C), 5-halo-cytosine (e.g., 5-iodo-cytosine), 5-hydroxymethyl-cytosine (hm5C), 1-methyl-pseudoisocytidine, pyrrolo-cytosine, pyrrolo-pseudoisocytidine, 2-thio-cytosine (s2C), 2-thio-5-methyl-cytosine, 4-thio-pseudoisocytidine, 4-thio-1-methyl-pseudoisocytidine, 4-thio-1-methyl-1-deaza-pseudoisocytidine, 1-methyl-1-deaza-pseudoisocytidine Idoisocytidine, Zebularine, 5-aza-zebularine, 5-methyl-zebularine, 5-aza-2-thio-zebularine, 2-thio-zebularine, 2-methoxy-cytosine, 2-methoxy-5-methyl-cytosine, 4-methoxy-pseudoisocytidine, 4-methoxy-1-methyl-pseudoisocytidine, Lysidine (k2C), 5,2'-O-dimethyl-cytidine (m5Cm), N4- These include acetyl-2'-O-methyl-cytidine (ac4Cm), N4,2'-O-dimethyl-cytidine (m4Cm), 5-formyl-2'-O-methyl-cytidine (f5Cm), N4,N4,2'-O-trimethyl-cytidine (m42Cm), 1-thio-cytosine, 5-hydroxy-cytosine, 5-(3-azidopropyl)-cytosine, and 5-(2-azidoethyl)-cytosine.

[0123] In some embodiments, the nucleobase is an alternative adenine. Exemplary nucleobases and nucleosides having an alternative adenine include 2-amino-purine, 2,6-diaminopurine, 2-amino-6-halo-purine (e.g., 2-amino-6-chloro-purine), 6-halo-purine (e.g., 6-chloro-purine), 2-amino-6-methyl-purine, 8-azido-adenine, 7-deaza-adenine, 7-deaza-8-aza-adenine, 7-deaza-2-amino-purine, 7-deaza-8-aza-2-amino-purine, 7-deaza-2,6-diaminopurine, 7-deaza-8 -aza-2,6-diaminopurine, 1-methyl-adenine (m1A), 2-methyl-adenine (m2A), N6-methyl-adenine (m6A), 2-methylthio-N6-methyl-adenine (ms2m6A), N6-isopentenyl-adenine (i6A), 2-methylthio-N6-isopentenyl-adenine (ms2i6A), N6-(cis-hydroxyisopentenyl)adenine (io6A), 2-methylthio-N6-(cis-hydroxyisopentenyl)adenine (ms2io6A), N6-glycinylcarboxamide N6-threonylcarbamoyl-adenine (g6A), N6-threonylcarbamoyl-adenine (t6A), N6-methyl-N6-threonylcarbamoyl-adenine (m6t6A), 2-methylthio-N6-threonylcarbamoyl-adenine (ms2g6A), N6,N6-dimethyl-adenine (m62A), N6-hydroxynorvalylcarbamoyl-adenine (hn6A), 2-methylthio-N6-hydroxynorvalylcarbamoyl-adenine (ms2hn6A), N6-acetyl-adenine (ac6A), 7-methyl -adenine, 2-methylthio-adenine, 2-methoxy-adenine, N6,2'-O-dimethyl-adenosine (m6Am), N6,N6,2'-O-trimethyl-adenosine (m62Am), 1,2'-O-dimethyl-adenosine (m1Am), 2-amino-N6-methyl-purine, 1-thio-adenine, 8-azido-adenine, N6-(19-amino-pentaoxanonadecyl)-adenine, 2,8-dimethyl-adenine, N6-formyl-adenine, and N6-hydroxymethyl-adenine.

[0124] In some embodiments, the nucleobase is a substitute guanine. Exemplary nucleobases and nucleosides having a substitute guanine include inosine (I), 1-methyl-inosine (m1I), wyosine (imG), methylwyosine (mimG), 4-demethyl-wyosine (imG-14), isowyosine (imG2), wyosine (yW), peroxywyosine (o2yW), hydroxywyosine (OHyW), incompletely modified hydroxywyosine (OHyW*), 7-deaza-guanine, queuosine, (Q), epoxyqueuosine (oQ), galactosyl-queuosine (galQ), mannosyl-queuosine (manQ), 7-cyano-7-deaza-guanine (preQ0), 7-aminomethyl-7-deaza-guanine (preQ1), archaeosine (G+), 7-deaza-8-aza-guanine, 6-thio-guanine, 6-thio-7-deaza-guanine, 6-thio-7-deaza-8-aza-guanine, 7-methyl-guanine (m7G), 6-thio-7 -methyl-guanine, 7-methyl-inosine, 6-methoxy-guanine, 1-methyl-guanine (m1G), N2-methyl-guanine (m2G), N2,N2-dimethyl-guanine (m22G), N2,7-dimethyl-guanine (m2,7G), N2,N2,7-dimethyl-guanine (m2,2,7G), 8-oxo-guanine, 7-methyl-8-oxo-guanine, 1-methyl-6-thio-guanine, N2-methyl-6-thio-guanine, N2,N2-dimethyl mGm), N2,N2-dimethyl-2'-O-methyl-guanosine (m22Gm), 1-methyl-2'-O-methyl-guanosine (m1Gm), N2,7-dimethyl-2'-O-methyl-guanosine (m2,7Gm), 2'-O-methyl-inosine (Im), 1,2'-O-dimethyl-inosine (m1Im), 1-thio-guanine, and O-6-methyl-guanine.

[0125] The alternative nucleobase of a nucleotide can independently be a purine, a pyrimidine, a purine or a pyrimidine analog. For example, the nucleobase can be an alternative to adenine, cytosine, guanine, uracil, or hypoxanthine. In some embodiments, nucleobases can also include, for example, natural and synthetic derivatives of bases, such as pyrazolo[3,4-d]pyrimidine, 5-methylcytosine (5-me-C), 5-hydroxymethylcytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-propynyluracil and cytosine, 6-azouracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo (e.g., 8-bromo), 8-amino, 8-thiol. , 8-thioalkyl, 8-hydroxy and other 8-substituted adenines and guanines, 5-halo, especially 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, deazaguanine, 7-deazaguanine, 3-deazaguanine, deazaadenine, 7-deazaadenine, 3-deazaadenine, pyrazolo[3,4-d]pyrimidines, imidazo[1,5-a]1,3,5 triazinones, 9-deazapurines, imidazo[4,5-d]pyrazines, thiazolo[4,5-d]pyrimidines, pyrazin-2-ones, 1,2,4-triazines, pyridazines; or 1,3,5 triazines. When nucleotides are designated using the abbreviations A, G, C, T, or U, each letter refers to a representative base and / or its derivatives, e.g., A includes adenine or an adenine analog, such as 7-deazaadenine.

[0126] Modifications in sugars A nucleoside comprises a sugar molecule (e.g., a 5-carbon or 6-carbon sugar, such as pentose, ribose, arabinose, xylose, glucose, galactose, or deoxy derivatives thereof) in combination with a nucleobase, while a nucleotide is a nucleoside that contains a phosphate group or an alternative group (e.g., boranophosphate, thiophosphate, selenophosphate, phosphonate, alkyl group, amidate, and glycerol). The nucleoside or nucleotide can be a standard species, e.g., a nucleoside or nucleotide that contains a standard nucleobase, sugar, and, in the case of a nucleotide, a phosphate group, or can be an alternative nucleoside or nucleotide that contains one or more alternative moieties. For example, the alternative nucleosides and nucleotides can be modified in the sugar of the nucleoside or nucleotide. In some embodiments, the alternative nucleoside or nucleotide has the structure

[0127] [ka]

[0128] Includes. In each of formulas IV, V, VI and VII: Each of m and n is independently an integer of 0 to 5; Each of U and U′ is independently O, S, N(R U ) nu , or C(R U ) nu where nu is an integer from 0 to 2, and each R U is independently H, halo, or optionally substituted alkyl; R 1’ , R 2’ , R 1” , R 2” , R 1 , R 2 , R 3 , R 4 , and R 5each, when present, is independently H, halo, hydroxy, thiol, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkoxy, optionally substituted alkoxyalkoxy, optionally substituted hydroxyalkoxy, optionally substituted amino, azido, optionally substituted aryl, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, optionally substituted aminoalkynyl, or absent; 3x And, R 1’ , R 1” , R 2’ , R 2” , or R 5 (e.g., R 1” and R 3x Combination of R 1” and R 3x Combination of R 2’ and R 3x Combination of R 2” and R 3x combination of, or R 5x and R 3x (combinations of) can be joined together to form an optionally substituted alkylene or an optionally substituted heteroalkylene, which, together with the carbons to which they are attached, provide an optionally substituted heterocyclyl (e.g., a bicyclic, tricyclic, or tetracyclic heterocyclyl), where R 5 And, R 1’ , R 1” , R 2’ , or R 2” (e.g., R 1’ and R 5 Combination of R 1” and R 5 Combination of R 2’ and R 5 combination of, or R 2” and R 5(combinations of) can be joined together to form an optionally substituted alkylene or an optionally substituted heteroalkylene, which, together with the carbons to which they are attached, provide an optionally substituted heterocyclyl (e.g., a bicyclic, tricyclic, or tetracyclic heterocyclyl), where R 4x And, R 1’ , R 1” , R 2’ , R 2” , R 3 , or R 5 can be joined together to form an optionally substituted alkylene or an optionally substituted heteroalkylene, which, together with the carbons to which they are attached, provide an optionally substituted heterocyclyl (e.g., a bicyclic, tricyclic, or tetracyclic heterocyclyl), each of m' and m" is independently an integer from 0 to 3 (e.g., 0 to 2, 0 to 1, 1 to 3, or 1 to 2); Y 1 , Y 2 , and Y 3 each independently represents O, S, Se, -NR N1 -, optionally substituted alkylene, or optionally substituted heteroalkylene, where R N1 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, or absent; Each Y 4 are independently H, hydroxy, thiol, boranyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted thioalkoxy, optionally substituted alkoxyalkoxy, or optionally substituted amino; Each Y 5is independently O, S, Se, optionally substituted alkylene (e.g., methylene), or optionally substituted heteroalkylene; B is a nucleobase, either modified or unmodified. In some embodiments, the 2'-hydroxy group (OH) can be modified or replaced with a number of different substituents. Exemplary substitutions at the 2'-position include, but are not limited to, H, azido, halo (e.g., fluoro), optionally substituted C 1-6 Alkyl (e.g., methyl), optionally substituted C 1-6 Alkoxy (e.g., methoxy or ethoxy), optionally substituted C 6-10 Aryloxy; optionally substituted C 3-8 Cycloalkyl; optionally substituted C 6-10 Aryl-C 1-6 Alkoxy, optionally substituted C 1-12 (heterocyclyl)oxy; sugar (e.g., ribose, pentose, or any described herein), polyethylene glycol (PEG), -O(CH2CH2O) n CH2CH2OR, where R is H or an optionally substituted alkyl and n is an integer from 0 to 20 (e.g., 0 to 4, 0 to 8, 0 to 10, 0 to 16, 1 to 4, 1 to 8, 1 to 10, 1 to 16, 1 to 20, 2 to 4, 2 to 8, 2 to 10, 2 to 16, 2 to 20, 4 to 8, 4 to 10, 4 to 16, and 4 to 20), "locked" nucleic acids (LNAs), where the 2'-hydroxy is 1-6 Alkylene or C 1-6 linked to the 4'-carbon of the same ribose sugar by a heteroalkylene bridge; exemplary bridges included methylene, propylene, ether, or amino bridges), aminoalkyl as defined herein, aminoalkoxy as defined herein, amino as defined herein; and amino acids as defined herein.

[0129] Generally, RNA contains the sugar group ribose, which is a five-membered ring with oxygen. Exemplary non-limiting alternative nucleotides include replacement of oxygen in ribose (e.g., with S, Se, or alkylenes such as methylene or ethylene), addition of double bonds (e.g., to replace ribose with cyclopentenyl or cyclohexenyl); ring contraction of ribose (e.g., to form cyclobutane or oxetane four-membered rings); ring expansion of ribose (e.g., to add additional carbon atoms, such as anhydrohexitol, altritol, mannitol, cyclohexanyl, cyclohexenyl, and morpholino (also having a phosphoramidate backbone). or to form 6- or 7-membered rings with heteroatoms), polycyclic forms (e.g., tricyclic and "unlocked" forms such as glycol nucleic acids (GNAs) (e.g., R-GNA or S-GNA, where the ribose is replaced with a glycol unit linked to a phosphodiester bond), threose nucleic acids (TNA, where the ribose is replaced with α-L-threofuranosyl-(3'→2')), and peptide nucleic acids (PNAs, where a 2-amino-ethyl-glycine bond replaces the ribose and phosphodiester backbone).

[0130] In some embodiments, the sugar group contains one or more carbons that have the opposite stereochemical configuration as the corresponding carbon in ribose. Thus, a polynucleotide molecule can include nucleotides that contain, for example, arabinose or L-ribose as the sugar.

[0131] In some embodiments, a polynucleotide comprises at least one nucleoside where the sugar is L-ribose, 2'-O-methyl-ribose, 2'-fluoro-ribose, arabinose, hexitol, LNA, or PNA.

[0132] Modifications in internucleoside linkages Alternative nucleotides may be modified in the internucleoside linkage (e.g., the phosphate backbone). As used herein, with respect to the polynucleotide backbone, the terms "phosphate" and "phosphodiester" are used interchangeably. The backbone phosphate group may be modified by replacing one or more of the oxygen atoms with different substituents.

[0133] Alternative nucleotides may include large substitutions of unmodified phosphate moieties with alternative internucleoside linkages as described herein. Examples of alternative phosphate groups include, but are not limited to, phosphorothioates, phosphoroselenates, boranophosphates, boranophosphate esters, hydrogen phosphonates, phosphoramidates, phosphorodiamidates, alkyl or aryl phosphonates, and phosphotriesters. Phosphorodithioates have both non-linked oxygens replaced by sulfur. Phosphate linkers may also be modified by replacing the linking oxygen with nitrogen (bridged phosphoramidates), sulfur (bridged phosphorothioates), and carbon (bridged methylene-phosphonates).

[0134] Alternative nucleosides and nucleotides may include replacement of one or more of the non-bridging oxygens with a borane moiety (BH3), sulfur (thio), methyl, ethyl, and / or methoxy. As a non-limiting example, two non-bridging oxygens at the same position (e.g., the alpha (α), beta (β), or gamma (γ) position) may be replaced with sulfur (thio) and methoxy.

[0135] Substitution of one or more oxygen atoms at the α-position of a phosphate moiety (e.g., α-thiophosphate) is provided to confer stability (e.g., against exonucleases and endonucleases) to RNA and DNA with non-natural phosphorothioate backbone linkages. Phosphorothioate DNA and RNA have increased nuclease resistance and therefore a longer half-life in the cellular environment.

[0136] Other internucleoside linkages that can be used in accordance with the present disclosure are described herein, including internucleoside linkages that do not contain a phosphorus atom. Internal ribosome entry site The polynucleotide may contain an internal ribosome entry site (IRES). The IRES may act as the sole ribosome binding site or as one of multiple ribosome binding sites of an mRNA. A polynucleotide containing more than one functional ribosome binding site may code for several peptides or polypeptides that are translated independently by the ribosome (e.g., polycistronic mRNA). When the polynucleotide is equipped with an IRES, a second translatable region is optionally further provided. Examples of IRES sequences that may be used according to the present disclosure include, but are not limited to, those derived from picornaviruses (e.g., FMDV), plague viruses (CFFV), polioviruses (PV), encephalomyocarditis viruses (ECMV), foot and mouth disease viruses (FMDV), hepatitis C virus (HCV), classical swine fever virus (CSFV), murine leukemia viruses (MLV), simian immunodeficiency viruses (SIV) or cricket paralysis virus (CrPV).

[0137] 5'-cap structure A polynucleotide (e.g., mRNA) may contain a 5'-cap structure. The 5'-cap structure of a polynucleotide is involved in nuclear export, enhances polynucleotide stability, and binds to mRNA cap-binding protein (CBP), which is involved in polynucleotide stability and translational competence within a cell through the binding of CBP to poly-A binding protein to form mature circular mRNA species. The cap also aids in the removal of 5'-proximal introns during mRNA splicing.

[0138] Endogenous polynucleotide molecules may be capped at the 5' end to form a 5'-ppp-5'-triphosphate linkage between the terminal guanosine cap residue of the polynucleotide and the 5'-terminal transcribed sense nucleotide. This 5'-guanylic acid cap may then be methylated to generate an N7-methyl-guanylic acid residue. The ribose sugar of the terminal and / or pre-terminal transcribed nucleotide at the 5' end of the polynucleotide may also be optionally 2'-O-methylated. 5'-cap removal by hydrolysis and cleavage of the guanylic acid cap structure may target the degradation of polynucleotide molecules, such as mRNA molecules.

[0139] Modifications to polynucleotides can generate non-hydrolyzable cap structures to prevent cap removal, thereby increasing polynucleotide half-life. Because cap structure hydrolysis requires cleavage of the 5'-ppp-5' phosphorodiester bond, alternative nucleotides can be used during the capping reaction. For example, Vaccinia Capping Enzyme from New England Biolabs (Ipswich, MA) can be used with α-thio-guanosine nucleotides according to the manufacturer's instructions to form phosphorothioate bonds in the 5'-ppp-5' cap. Additional alternative guanosine nucleotides, such as α-methyl-phosphonate and seleno-phosphate nucleotides, can be used.

[0140] Further modifications include, but are not limited to, 2'-O-methylation of the ribose sugar of the 5'-terminus and / or penultimate nucleotide of the polynucleotide at the 2'-hydroxy group of the sugar (described above).Several different 5'-cap structures can be used to create the 5'-cap of a polynucleotide, such as an mRNA molecule.

[0141] 5'-cap structures include those described in International Patent Publication Nos. WO2008127688, WO2008016473, and WO2011015347, each of which is incorporated herein by reference.

[0142] A cap analog, also referred to herein as a synthetic cap analog, chemical cap, chemical cap analog, or structural or functional cap analog, differs in its chemical structure from the natural (i.e., endogenous, wild-type, or physiological) 5'-cap while retaining cap function. Cap analogs can be synthesized / linked to a polynucleotide chemically (i.e., non-enzymatically) or enzymatically.

[0143] For example, an anti-reverse cap analog (ARCA) cap contains two guanosines linked by 5'-5'-triphosphate groups, where one guanosine contains an N7-methyl group as well as a 3'-O-methyl group (i.e., N7,3'-O-dimethyl-guanosine-5'-triphosphate-5'-guanosine, m7G-3'mppp-G, which may also be referred to as 3'O-Me-m7G(5')ppp(5')G). The 3'-O atom of the other unmodified guanosine is linked to the 5'-terminal nucleotide of a capped polynucleotide (e.g., an mRNA). The N7- and 3'-O-methylated guanosine provide the terminal portion of the capped polynucleotide (e.g., an mRNA).

[0144] Another exemplary cap is mCAP, which is similar to ARCA but has a 2'-O-methyl group on the guanosine (i.e., N7,2'-O-dimethyl-guanosine-5'-triphosphate-5'-guanosine, mCAP). 7 Gm-ppp-G).

[0145] The cap can be a dinucleotide cap analog, non-limiting examples include those described in U.S. Pat. No. 8,519,110 (the cap structures of which are incorporated herein by reference).

[0146] Alternatively, the cap analog can be an N7-(4-chlorophenoxyethyl) substituted dinucleotide cap analog known in the art and / or described herein. Non-limiting examples of N7-(4-chlorophenoxyethyl) substituted dinucleotide cap analogs include N7-(4-chlorophenoxyethyl)-G(5')ppp(5')G and N7-(4-chlorophenoxyethyl)-m3'-OG(5')ppp(5')G cap analogs (see, e.g., the various cap analogs and methods of synthesizing cap analogs described in Kore et al. Bioorganic & Medicinal Chemistry 2013 21:4570-4574, the cap structures of which are incorporated herein by reference). In some embodiments, a cap analog useful for the polynucleotides of the present disclosure is a 4-chloro / bromophenoxyethyl analog.

[0147] Although cap analogs allow for the simultaneous capping of polynucleotides in in vitro transcription reactions, up to 20% of the transcripts remain uncapped, which, together with the structural differences of the cap analogs from the endogenous 5'-cap structure of polynucleotides produced by the endogenous cellular transcription machinery, can result in reduced translational competence and reduced cellular stability.

[0148] Alternative polynucleotides can also be post-transcriptionally capped using enzymes to create more authentic 5'-cap structures. As used herein, the phrase "more authentic" refers to features that structurally or functionally resemble or mimic endogenous or wild-type features. That is, a "more authentic" feature better represents an endogenous, wild-type, natural or physiological cellular function and / or structure compared to a synthetic feature or analog of the prior art, or outperforms the corresponding endogenous, wild-type, natural or physiological feature in one or more respects. Non-limiting examples of more authentic 5'-cap structures useful for the polynucleotides of the present disclosure are those that have, among others, increased binding of cap-binding proteins, increased half-life, reduced susceptibility to 5'-endonucleases, and / or decreased 5'-cap removal compared to synthetic 5'-cap structures (or wild-type, natural or physiological 5'-cap structures) known in the art. For example, recombinant vaccinia virus capping enzyme and recombinant 2'-O-methyltransferase enzyme can form a standard 5'-5'-triphosphate linkage between the 5'-terminal nucleotide of a polynucleotide and a guanosine cap nucleotide, where the cap guanosine contains an N7-methylation and the 5'-terminal nucleotide of the polynucleotide contains a 2'-O-methyl. Such a structure is referred to as a Cap 1 structure. This cap results in higher translational capacity, cellular stability, and reduced activation of cellular pro-inflammatory cytokines, for example, compared to other 5' cap analog structures known in the art. Other exemplary cap structures include 7mG(5')ppp(5')N,pN2p (cap 0), 7mG(5')ppp(5')NlmpNp (cap 1), 7mG(5')-ppp(5')NlmpN2mp (cap 2), and m(7)Gpppm(3)(6,6,2')Apm(2')Apm(2')Cpm(2)(3,2')Up (cap 4).

[0149] Because the alternative polynucleotides can be capped post-transcriptionally, and because this process is more efficient, nearly 100% of the alternative polynucleotides can be capped, as opposed to about 80% when the cap analog is ligated to the polynucleotide during the in vitro transcription reaction.

[0150] The 5'-end cap may comprise an endogenous cap or a cap analog. The 5'-end may comprise a guanosine analog. Useful guanosine analogs include inosine, N1-methyl-guanosine, 2'-fluoro-guanosine, 7-deaza-guanosine, 8-oxo-guanosine, 2-amino-guanosine, LNA-guanosine, and 2-azido-guanosine.

[0151] In some embodiments, the polynucleotide contains a modified 5'-cap. Modifications at the 5'-cap can increase the stability of the polynucleotide, increase the half-life of the polynucleotide, and increase the efficiency of polynucleotide translation. Modified 5'-caps include, but are not limited to, one or more of the following modifications: modifications at the 2' and / or 3' positions of the capped guanosine triphosphate (GTP), a sugar ring oxygen replacement with a methylene moiety (CH2) (thus generating a carbocyclic ring), a modification at the triphosphate bridge portion of the cap structure, or a modification at the nucleobase (G) portion.

[0152] 5'-UTR A 5'-UTR may be provided as a flanking region to a polynucleotide (e.g., an mRNA). A 5'-UTR may be homologous or heterologous to the coding region found in the polynucleotide. Multiple 5'-UTRs may be included in a flanking region and may be of the same or different sequence. Any portion (including none) of a flanking region may be codon optimized and may independently contain one or more different structural or chemical modifications before and / or after codon optimization.

[0153] Presented in Table 21 of U.S. Provisional Patent Application No. 61 / 775,509, and Tables 21 and 22 of U.S. Provisional Patent Application No. 61 / 829,372, which are incorporated herein by reference, are lists of alternative polynucleotide (e.g., mRNA) start and stop sites. In Table 21, each 5'-UTR (5'-UTR-005 to 5'-UTR 68511) is identified by its start and stop sites relative to its native or wild-type (homologous) transcript (the identification number used in the ENST; ENSEMBL database).

[0154] A 5'-UTR heterologous to the coding region of a modified polynucleotide (e.g., mRNA) can be engineered to modify one or more properties of the polynucleotide (e.g., mRNA). The polynucleotide (e.g., mRNA) can then be administered to a cell, tissue, or organism, and results such as protein levels, localization, and / or half-life can be measured to assess the beneficial effect that the heterologous 5'-UTR may have over an alternative polynucleotide (mRNA). Mutants of the 5'-UTR can be used in which one or more nucleotides, including A, T, C, or G, are added or removed from the end. The 5'-UTR can also be codon-optimized or modified in any manner described herein.

[0155] 5'-UTR, 3'-UTR, and translational enhancer elements (TEEs) The 5'-UTR of a polynucleotide (e.g., an mRNA) may contain at least one translation enhancer element. The term "translation enhancer element" refers to a sequence that increases the amount of a polypeptide or protein produced from a polynucleotide. As a non-limiting example, a TEE may be located between a transcription promoter and a start codon. A polynucleotide (e.g., an mRNA) having at least one TEE in its 5'-UTR may include a cap in the 5'-UTR. Additionally, at least one TEE may be located in the 5'-UTR of a polynucleotide (e.g., an mRNA) to effect cap-dependent or cap-independent translation.

[0156] In one embodiment, TEEs are conserved elements in UTRs that can facilitate the translational activity of polynucleotides, including but not limited to cap-dependent or cap-independent translation. The conservation of these sequences has been previously shown by Panek et al. (Nucleic Acids Research, 2013, 1-10) for 14 species, including humans.

[0157] In one non-limiting example, a known TEE can be in the 5'-leader of the Gtx homeodomain protein (Chappell et al., Proc. Natl. Acad. Sci. USA 101:9590-9594, 2004, which TEE is incorporated herein by reference).

[0158] In another non-limiting example, TEEs are disclosed in U.S. Patent Publication Nos. 2009 / 0226470 and 2013 / 0177581, International Patent Publication Nos. WO2009 / 075886, WO2012 / 009644, and WO1999 / 024595, and U.S. Patent Nos. 6,310,197 and 6,849,405, the respective TEE sequences of which are incorporated herein by reference.

[0159] In yet another non-limiting example, the TEE can be an internal ribosome entry site (IRES), HCV-IRES or IRES element, such as, but not limited to, those described in U.S. Pat. No. 7,468,275, U.S. Patent Application Publication Nos. 2007 / 0048776 and 2011 / 0124100, and International Patent Publication Nos. WO2007 / 025008 and WO2001 / 055369, the respective IRES sequences of which are incorporated herein by reference. IRES elements include, but are not limited to, Gtx sequences (e.g., Gtx9-nt, Gtx8-nt, Gtx7-nt) described by Chappell et al. (Proc. Natl. Acad. Sci. USA 101:9590-9594, 2004) and Zhou et al. (PNAS 102:6273-6278, 2005), and in U.S. Patent Publication Nos. 2007 / 0048776 and 2011 / 0124100 and International Patent Publication No. WO2007 / 025008, the IRES sequences of each of which are incorporated herein by reference.

[0160] "Translation enhancer polynucleotides" are exemplified herein and / or disclosed in the art (e.g., U.S. Pat. Nos. 6,310,197, 6,849,405, 7,456,273, 7,183,395, U.S. Patent Application Publication Nos. 20090 / 226470, 2007 / 0048776, 2011 / 0124100, 2009 / 009304, and the like). See, for example, International Patent Publication Nos. WO2009 / 075886, WO2007 / 025008, WO2012 / 009644, WO2001 / 055371, WO1999 / 024595, and European Patent Nos. 2610341 and 2610340, the TEE sequences of each of which are incorporated herein by reference. A polynucleotide that includes a specific TEE, a homologue, or a functional derivative thereof. One or more copies of a specific TEE may be present in a polynucleotide (e.g., mRNA). A TEE in a translation enhancer polynucleotide may be configured in one or more sequence segments. A sequence segment may carry one or more of the specific TEEs exemplified herein, each TEE being present in one or more copies. When multiple sequence segments are present in a translation enhancer polynucleotide, they may be homologous or heterologous. Thus, multiple sequence segments in a translation enhancer polynucleotide may carry the same or different types of the specific TEEs exemplified herein, the same or different number of copies of each of the specific TEEs, and / or the same or different configurations of TEEs within each sequence segment.

[0161] Polynucleotides (e.g., mRNA) may be prepared using methods described in International Patent Publication Nos. WO1999 / 024595, WO2012 / 009644, WO2009 / 075886, WO2007 / 025008, WO1999 / 024595, European Patent Publication Nos. 2610341 and 2610340, U.S. Patent Nos. 6,310,197, 6,849,405, 7,456,2 73, 7,183,395, and U.S. Patent Application Publication Nos. 2009 / 0226470, 2011 / 0124100, 2007 / 0048776, 2009 / 0093049, and 2013 / 0177581, the TEE sequences of each of which are incorporated herein by reference. The TEE may be located in the 5'-UTR of a polynucleotide (e.g., an mRNA).

[0162] Polynucleotides (e.g., mRNA) can be prepared using methods described in U.S. Patent Application Publication Nos. 2009 / 0226470, 2007 / 0048776, 2013 / 0177581, and 2011 / 0124100, International Patent Publication Nos. WO1999 / 024595, WO2012 / 009644, WO2009 / 075886, and WO2007 / 025008, European Patent Publication Nos. 2610341 and 2610340, U.S. Patent Nos. 6,310,197, 6,310,198, 6,310,19 ... Nos. 7,849,405, 7,456,273, and 7,183,395 (the TEE sequences of each of which are incorporated by reference herein) may include at least one TEE that has at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% identity to a TEE described in any of the above-mentioned US Pat.

[0163] The 5'-UTR of a polynucleotide (e.g., mRNA) may comprise at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, or more than 60 TEE sequences. The TEE sequences in the 5'-UTR of a polynucleotide (e.g., mRNA) may be the same or different TEE sequences. The TEE sequences may be in a pattern such as ABABAB, AABBABBAABB, or ABCABCABC, or variations thereof, repeated once, twice, or more than three times. In these patterns, each letter, A, B, or C, represents a different TEE sequence at the nucleotide level.

[0164] In some embodiments, the 5'-UTR may include a spacer separating the two TEE sequences. As a non-limiting example, the spacer may be a 15 nucleotide spacer and / or other spacers known in the art. As another non-limiting example, the 5'-UTR may include a TEE sequence-spacer module that is repeated at least once, at least twice, at least three times, at least four times, at least five times, at least six times, at least seven times, at least eight times, at least nine times, or ten or more times in the 5'-UTR.

[0165] In some embodiments, the spacer separating the two TEE sequences may include other sequences known in the art that may regulate translation of a polynucleotide (e.g., an mRNA) of the present disclosure, such as, but not limited to, an miR sequence (e.g., an miR binding site and an miR seed). As a non-limiting example, each spacer used to separate the two TEE sequences may include a different miR sequence or a component of a miR sequence (e.g., a miR seed sequence).

[0166] In some embodiments, the TEE in the 5'-UTR of a polynucleotide (e.g., an mRNA) is selected from the group consisting of those described in U.S. Patent Application Publication Nos. 2009 / 0226470, 2007 / 0048776, 2013 / 0177581, and 2011 / 0124100, International Patent Publication Nos. WO1999 / 024595, WO2012 / 009644, WO2009 / 075886, and WO2007 / 025008, European Patent Publication Nos. 2610341 and 2610340, and U.S. Patent Nos. 6,310,197, 6,849,405, 7,456,277, and 7,566,278. No. 7,183,395, and No. 7,183,395, the TEE sequences of which are each incorporated herein by reference. In some embodiments, the TEE in the 5'-UTR of a polynucleotide (e.g., an mRNA) of the present disclosure is selected from the group consisting of those described in U.S. Patent Publication Nos. 2009 / 0226470, 2007 / 0048776, 2013 / 0177581, and 2011 / 0124100, International Patent Publication Nos. WO1999 / 024595, WO2012 / 009644, WO2009 / 075886, and WO2007 / 025008, European Patent Publication No. Nos. 6,310,197, 6,849,405, 7,456,273, and 7,183,395 (the TEE sequences of each of which are incorporated herein by reference).

[0167] In some cases, the TEE in the 5'-UTR of a polynucleotide (e.g., an mRNA) of the disclosure may be selected from the group consisting of the TEEs described in Chappell et al. (Proc. Natl. Acad. Sci. USA 101:9590-9594, 2004) and Zhou et al. (PNAS 102:6273-6278, 2005), and Wellensiek et al. (Genome-wide profiling of human cap-independent translation-enhancing elements, Nature Methods, 2013; DOI:10.1038 / NMETH.2522), the TEE sequences disclosed in Supplementary Table 1 and Supplementary Table 2 (each of which TEE sequences are incorporated herein by reference). In some embodiments, the TEE in the 5'-UTR of a polynucleotide (e.g., an mRNA) of the present disclosure may comprise at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99% or more of ...2 and Supplementary Table 3 (each of which TEE sequences are incorporated herein by reference). (Proc. Natl. Acad. Sci. USA 101:9590-9594, 2004), Zhou et al. (PNAS 102:6273-6278, 2005), and Wellensiek et al. (Genome-wide profiling of human cap-independent translation-enhancing elements, Nature Methods, 2013; DOI:10.1038 / NMETH.2522), each of which TEE sequences are incorporated herein by reference.

[0168] In some embodiments, the TEE used in the 5'-UTR of a polynucleotide (e.g., an mRNA) is an IRES sequence, such as, but not limited to, those described in U.S. Pat. No. 7,468,275 and International Patent Publication No. WO2001 / 055369, the TEE sequences of each of which are incorporated herein by reference.

[0169] In some embodiments, TEEs used in the 5'-UTR of a polynucleotide (e.g., an mRNA) may be identified by the methods described in U.S. Patent Application Publication Nos. 2007 / 0048776 and 2011 / 0124100 and International Patent Publication Nos. WO2007 / 025008 and WO2012 / 009644, each of which is incorporated herein by reference.

[0170] In some embodiments, the TEE used in the 5'-UTR of a polynucleotide (e.g., mRNA) of the present disclosure may be a transcriptional regulatory element as described in U.S. Patent Nos. 7,456,273 and 7,183,395, U.S. Patent Application Publication No. 2009 / 0093049, and International Publication No. WO2001 / 055371, each of which TEE sequences are incorporated herein by reference. Transcriptional regulatory elements may be identified by methods known in the art, such as, but not limited to, those described in U.S. Patent Nos. 7,456,273 and 7,183,395, U.S. Patent Application Publication No. 2009 / 0093049, and International Publication No. WO2001 / 055371, each of which methods are incorporated herein by reference.

[0171] Further, in some embodiments, the TEE used in the 5'-UTR of a polynucleotide (e.g., an mRNA) is a polynucleotide or portion thereof described in U.S. Pat. Nos. 7,456,273 and 7,183,395, U.S. Patent Application Publication No. 2009 / 0093049, and International Publication No. WO2001 / 055371, the TEE sequences of each of which are incorporated herein by reference.

[0172] A 5'-UTR comprising at least one TEE as described herein can be incorporated into a monocistronic sequence, such as, but not limited to, a vector system or a polynucleotide vector. By way of non-limiting example, vector systems and polynucleotide vectors can include those described in U.S. Patent Nos. 7,456,273 and 7,183,395, U.S. Patent Application Publication Nos. 2007 / 0048776, 2009 / 0093049 and 2011 / 0124100, and International Patent Publication Nos. WO2007 / 025008 and WO2001 / 055371, the TEE sequences of each of which are incorporated herein by reference.

[0173] The TEEs described herein can be located in the 5'-UTR and / or the 3'-UTR of a polynucleotide (e.g., an mRNA). The TEE located in the 3'-UTR can be the same and / or different from the TEEs described for location in the 5'-UTR and / or incorporation into the 5'-UTR.

[0174] In some embodiments, the 3'-UTR of a polynucleotide (e.g., mRNA) may comprise at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, or more than 60 TEE sequences. The TEE sequences in the 3'-UTR of a polynucleotide (e.g., mRNA) of the present disclosure may be the same or different TEE sequences. The TEE sequences may be in a pattern such as ABABAB, AABBABBAABB, or ABCABCABC, or variations thereof, repeated once, twice, or more than three times. In these patterns, each letter, A, B, or C, represents a different TEE sequence at the nucleotide level.

[0175] In one example, the 3'-UTR can include a spacer separating the two TEE sequences. As a non-limiting example, the spacer can be a 15 nucleotide spacer and / or other spacers known in the art. As another non-limiting example, the 3'-UTR can include a TEE sequence-spacer module that is repeated at least once, at least twice, at least three times, at least four times, at least five times, at least six times, at least seven times, at least eight times, at least nine times, or ten or more times in the 3'-UTR.

[0176] In some embodiments, the spacer separating the two TEE sequences can include other sequences known in the art that can regulate translation of a polynucleotide (e.g., an mRNA) of the present disclosure, such as, but not limited to, the miR sequences described herein (e.g., miR binding sites and miR seeds). As a non-limiting example, each spacer used to separate the two TEE sequences can include a different miR sequence or a component of a miR sequence (e.g., a miR seed sequence).

[0177] In some embodiments, incorporation of the miR sequence and / or the TEE sequence alters the shape of the stem-loop region, which can increase and / or decrease translation (see, e.g., Kedde et al., Nature Cell Biology 2010 12(10):1014-20, incorporated herein by reference in its entirety).

[0178] Stem Loop A polynucleotide (e.g., mRNA) may include a stem loop, such as, but not limited to, a histone stem loop. A stem loop may be a nucleotide sequence that is about 25 or about 26 nucleotides in length, such as, but not limited to, those described in International Patent Publication No. WO2013 / 103659, which is incorporated herein by reference. A histone stem loop may be located 3' to a coding region (e.g., at the 3' end of a coding region). As a non-limiting example, a stem loop may be located at the 3' end of a polynucleotide described herein. In some embodiments, a polynucleotide (e.g., mRNA) includes two or more stem loops (e.g., two stem loops). Examples of stem loop sequences are described in International Patent Publication Nos. WO2012 / 019780 and WO201502667, which stem loop sequences are incorporated herein by reference. In some embodiments, a polynucleotide includes the stem loop sequence CAAAGGCTCTTTTCAGAGCCACCA (SEQ ID NO: 1). In other cases, the polynucleotide includes the stem-loop sequence CAAAGGCUCUUUUCAGAGCCACCA (SEQ ID NO:2).

[0179] The stem loop may be located in the second terminal region of the polynucleotide. As a non-limiting example, the stem loop may be located in an untranslated region (e.g., 3'-UTR) of the second terminal region. In some embodiments, polynucleotides, such as, but not limited to, mRNAs that contain histone stem loops, can be stabilized by the addition of a 3'-stabilizing region (e.g., a 3'-stabilizing region that includes at least one chain-terminating nucleoside). Without intending to be bound by theory, the addition of at least one chain-terminating nucleoside can slow down degradation of the polynucleotide, thereby increasing the half-life of the polynucleotide.

[0180] In some embodiments, polynucleotides, such as, but not limited to, mRNAs that contain histone stem loops, can be stabilized by modifications to the 3'-region of the polynucleotide that can prevent and / or inhibit the addition of oligo(U) (see, e.g., International Patent Publication No. WO2013 / 103659).

[0181] Additionally, in some embodiments, polynucleotides such as, but not limited to, mRNAs containing histone stem loops can be stabilized by the addition of oligonucleotides that terminate in 3'-deoxynucleosides, 2',3'-dideoxynucleosides, 3'-O-methyl nucleosides, 3'-O-ethyl nucleosides, 3'-arabinosides, and other modified nucleosides known in the art and / or described herein.

[0182] In some embodiments, polynucleotides of the present disclosure may comprise a histone stem loop, a poly-A tract, and / or a 5'-cap structure. The histone stem loop may precede and / or follow the poly-A tract. Polynucleotides comprising histone stem loop and poly-A tract sequences may comprise a chain-terminating nucleoside as described herein.

[0183] In some embodiments, polynucleotides of the present disclosure may comprise histone stem loop and 5'-cap structures. The 5'-cap structures may include, but are not limited to, those described herein and / or known in the art.

[0184] In some embodiments, the conserved stem-loop region may comprise a miR sequence as described herein. As a non-limiting example, the stem-loop region may comprise a seed sequence of a miR sequence as described herein. In another non-limiting example, the stem-loop region may comprise a miR-122 seed sequence.

[0185] In some cases, the conserved stem-loop region may comprise a miR sequence described herein and may also comprise a TEE sequence. In some embodiments, incorporation of the miR and / or TEE sequences alters the shape of the stem-loop region, which may increase and / or decrease translation (see, e.g., Kedde et al. A Pumilio-induced RNA structure switch in p27-3'UTR controls miR-221 and miR-22 accessibility. 2010, incorporated herein by reference in its entirety).

[0186] The polynucleotide may comprise at least one histone stem loop and a poly-A region or a polyadenylation signal. Non-limiting examples of polynucleotide sequences encoding at least one histone stem loop and a poly-A region or a polyadenylation signal are described in International Patent Publication Nos. WO2013 / 120497, WO2013 / 120629, WO2013 / 120500, WO2013 / 120627, WO2013 / 120498, WO2013 / 120626, WO2013 / 120499 and WO2013 / 120628, the sequences of each of which are incorporated herein by reference. In some cases, the polynucleotide encoding the histone stem loop and poly-A region or polyadenylation signal may encode a pathogen antigen or a fragment thereof, such as the polynucleotide sequences described in International Patent Publication Nos. WO2013 / 120499 and WO2013 / 120628, both of which sequences are incorporated herein by reference. In some embodiments, the polynucleotide encoding the histone stem loop and poly-A region or polyadenylation signal may encode a therapeutic protein, such as the polynucleotide sequences described in International Patent Publication Nos. WO2013 / 120497 and WO2013 / 120629, both of which sequences are incorporated herein by reference. In some embodiments, the polynucleotide encoding the histone stem loop and poly-A region or polyadenylation signal may encode a tumor antigen or a fragment thereof, such as the polynucleotide sequences described in International Patent Publication Nos. WO2013 / 120500 and WO2013 / 120627, both of which sequences are incorporated herein by reference. In some embodiments, the polynucleotide encoding the histone stem loop and poly-A region or polyadenylation signal may encode an allergenic antigen or an autoimmune autoantigen, such as the polynucleotide sequences described in International Patent Publication Nos. WO2013 / 120498 and WO2013 / 120626, both of which sequences are incorporated herein by reference.

[0187] Poly-A region A polynucleotide or nucleic acid (e.g., mRNA) may contain a polyA sequence and / or a polyadenylation signal. The polyA sequence may be composed entirely or predominantly of adenine nucleotides or analogs or derivatives thereof. The polyA sequence may be a tail located adjacent to the 3' untranslated region of the nucleic acid.

[0188] During RNA processing, long chains of adenosine nucleotides (poly-A regions) are usually added to messenger RNA (mRNA) molecules to increase the stability of the molecule. Immediately after transcription, the 3' end of the transcript is cleaved to release a 3'-hydroxyl. Poly-A polymerase then adds chains of adenosine nucleotides to the RNA. This process, called polyadenylation, adds poly-A regions that are 100-250 residues in length.

[0189] The length of the unique poly-A region can confer several advantages to the modified polynucleotides of the present disclosure. Generally, the length of the poly-A region of the present disclosure is at least 30 nucleotides.In some embodiments, the length is at least 40 nucleotides, at least 50 nucleotides, at least 60 nucleotides, at least 70 nucleotides, at least 80 nucleotides, at least 90 nucleotides, at least 100 nucleotides, at least 120 nucleotides, at least 140 nucleotides, at least 160 nucleotides, at least 180 nucleotides, at least 200 nucleotides, at least 250 nucleotides, at least 300 nucleotides, at least 350 nucleotides, at least 400 nucleotides, at least 450 nucleotides, at least 500 nucleotides, at least 600 nucleotides, at least 700 nucleotides, at least 800 nucleotides, at least 900 nucleotides, at least 1000 nucleotides, at least 1200 nucleotides, at least 1400 nucleotides, at least 1600 nucleotides, at least 1800 nucleotides, at least 2000 nucleotides, at least 2500 nucleotides, or at least 3000 nucleotides.

[0190] In some embodiments, the poly-A region can be 80, 120, 160 nucleotides in length in the modified polynucleotide molecules described herein.

[0191] In some embodiments, the poly-A region can be 20, 40, 80, 100, 120, 140 or 160 nucleotides in length in the modified polynucleotide molecules described herein.

[0192] In some embodiments, the poly-A region is designed for the entire length of the modified polynucleotide. This design can be based on the length of the coding region of the modified polynucleotide, the length of a particular feature or region of the modified polynucleotide (such as mRNA), or based on the length of the final product expressed from the modified polynucleotide. Compared to any feature of the modified polynucleotide (e.g., other than the mRNA portion that contains the poly-A region), the poly-A region can be 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100% longer in length than the additional feature. The poly-A region can also be designed as part of the modified polynucleotide to which it belongs. In this regard, the poly-A region can be 10, 20, 30, 40, 50, 60, 70, 80, or 90% or more of the total length of the construct or the total length of the construct minus the poly-A region.

[0193] In some cases, engineered binding sites and / or conjugation of a polynucleotide (e.g., mRNA) for poly-A binding protein can be used to enhance expression. The engineered binding site can be a sensor sequence that can act as a binding site for a ligand of the local microenvironment of the polynucleotide (e.g., mRNA). As a non-limiting example, a polynucleotide (e.g., mRNA) can include at least one engineered binding site to modify the binding affinity of poly-A binding protein (PABP) and its analogs. Incorporation of at least one engineered binding site can increase the binding affinity of PABP and its analogs.

[0194] Additionally, multiple different polynucleotides (e.g., mRNAs) can be linked together to PABP (poly-A binding protein) via their 3' ends using modified nucleotides at the 3' end of the poly-A region. Transfection experiments can be performed in relevant cell lines and protein production can be assayed by ELISA at 12 hours, 24 hours, 48 ​​hours, 72 hours, and 7 days after transfection. As a non-limiting example, transfection experiments can be used to evaluate the effect on the binding affinity of PABP or its analogs as a result of the addition of at least one engineered binding site.

[0195] In some cases, poly-A regions may be used to regulate translation initiation. Without intending to be bound by theory, poly-A regions may be essential for protein synthesis because they recruit PABP, which can then interact with the translation initiation complex.

[0196] In some embodiments, a poly-A region may also be used in the present disclosure to protect against 3'-5'-exonuclease digestion. In some embodiments, the polynucleotide (e.g., mRNA) may include a poly-AG quartet. A G-quartet is a cyclic hydrogen-bonded array of four guanosine nucleotides that can be formed by G-rich sequences in both DNA and RNA. In this embodiment, the G-quartet is incorporated at the end of a poly-A region. The resulting polynucleotide (e.g., mRNA) may be assayed for stability, protein production, and other parameters including half-life at various time points. It has been discovered that poly-AG quartets result in protein production equivalent to at least 75% of that seen with only a 120-nucleotide poly-A region.

[0197] In some embodiments, a polynucleotide (e.g., an mRNA) may include a poly-A region and may be stabilized by the addition of a 3'-stabilizing region. A polynucleotide (e.g., an mRNA) that includes a poly-A region may further include a 5'-cap structure.

[0198] In some embodiments, a polynucleotide (e.g., an mRNA) can include a poly-AG quartet. A polynucleotide (e.g., an mRNA) that includes a poly-AG quartet can further include a 5'-cap structure.

[0199] In some embodiments, 3'-stabilization regions that can be used to stabilize polynucleotides (e.g., mRNAs) that contain poly-A tracts or poly-AG quartets can be, but are not limited to, those described in International Patent Publication No. WO2013 / 103659, the poly-A tracts and poly-AG quartets of which are incorporated herein by reference. In some embodiments, 3'-stabilizing regions that may be used in the present disclosure include chain-terminating nucleosides such as 3'-deoxyadenosine (cordycepin), 3'-deoxyuridine, 3'-deoxycytosine, 3'-deoxyguanosine, 3'-deoxythymine, 2',3'-dideoxynucleosides, e.g., 2',3'-dideoxyadenosine, 2',3'-dideoxyuridine, 2',3'-dideoxycytosine, 2',3'-dideoxyguanosine, 2',3'-dideoxythymine, 2'-deoxynucleosides, or O-methylnucleosides.

[0200] In some embodiments, polynucleotides such as, but not limited to, mRNAs that contain polyA tracts or poly-AG quartets can be stabilized by modifications to the 3'-region of the polynucleotide that can prevent and / or inhibit the addition of oligo(U) (see, e.g., International Patent Publication No. WO2013 / 103659).

[0201] In some embodiments, polynucleotides such as, but not limited to, mRNAs containing poly-A regions or poly-AG quartets can be stabilized by the addition of oligonucleotides that terminate in 3'-deoxynucleosides, 2',3'-dideoxynucleosides, 3'-O-methyl nucleosides, 3'-O-ethyl nucleosides, 3'-arabinosides, and other modified nucleosides known in the art and / or described herein.

[0202] Chain-terminating nucleosides Nucleic acids may include chain-terminating nucleosides. For example, chain-terminating nucleosides may include nucleosides deoxygenated at the 2' and / or 3' positions of their sugar groups. Such species include 3'-deoxyadenosine (cordycepin), 3'-deoxyuridine, 3'-deoxycytosine, 3'-deoxyguanosine, 3'-deoxythymine, and 2',3'-dideoxynucleosides, such as 2',3'-dideoxyadenosine, 2',3'-dideoxyuridine, 2',3'-dideoxycytosine, 2',3'-dideoxyguanosine, and 2',3'-dideoxythymine.

[0203] Lipids and Lipid Mixtures In some embodiments, the lipid is an ionizable lipid. In some embodiments, the lipid is a phospholipid.

[0204] In some embodiments, the lipid is a PEG lipid. In some embodiments, the lipid is a structured lipid. In some embodiments, the lipid mixture comprises ionizable lipids.

[0205] In some embodiments, the lipid mixture comprises phospholipids. In some embodiments, the lipid mixture includes PEG lipids. In some embodiments, the lipid mixture comprises structured lipids.

[0206] In some embodiments, the lipid mixture comprises ionizable lipids, phospholipids, PEG lipids, structured lipids, or any combination thereof. Ionizable lipids In some embodiments, the ionizable lipid of the present disclosure has the formula (IL-I):

[0207] [ka]

[0208] or an N-oxide thereof, or a salt or isomer thereof, wherein R 1 is C 5-30 Alkyl, C 5-20 Alkenyl, -R * -YR", -YR", and -R"M'R'; R 2 and R 3 are independently H, C 1-14 Alkyl, C 2-14 Alkenyl, -R * YR”, -YR”, and -R * OR” or R 2 and R 3 together with the atom to which they are attached form a heterocyclic or carbocyclic ring, R 4 is hydrogen, C 3-6 Carbocyclic ring, -(CH2) n Q, -(CH2) n CHQR, -(CH2) o C(R 10 )2(CH2) n-o Q, -CHQR, -CQ(R)2, -C(O)NQR, and unsubstituted C 1-6 alkyl, where Q is a carbocycle, a heterocycle, -OR, -O(CH2), n N(R)2, -C(O)OR, -OC(O)R, -CX3, -CX2H, -CXH2, -CN, -N(R)2, -C(O)N(R)2, -N(R)C(O)R, -N(R)S(O)2R, -N(R)C(O)N(R)2, -N(R)C(S)N(R)2, -N(R)R8 , -N(R)S(O)2R 8 , -O(CH2) n OR, -N(R)C(=NR 9 )N(R)2, -N(R)C(=CHR 9 )N(R)2, -OC(O)N(R)2, -N(R)C(O)OR, -N(OR)C(O)R, -N(OR)S(O)2R, -N(OR)C(O)OR, -N(OR)C(O)N(R)2, -N(OR)C(S)N(R)2, -N(OR)C(=NR 9 )N(R)2, -N(OR)C(=CHR 9 )N(R)2, -C(=NR 9 )N(R)2, -C(=NR 9 )R, -C(O)N(R)OR, -(CH2) n -N(R)2, and -C(R)N(R)2C(O)OR, each o is independently selected from 1, 2, 3, and 4, and each n is independently selected from 1, 2, 3, 4, and 5; Each R 5 are independently OH, C 1-3 Alkyl, C 2-3 alkenyl, and H; Each R 6 are independently OH, C 1-3 Alkyl, C 2-3 alkenyl, and H; M and M' are independently selected from -C(O)O-, -OC(O)-, -OC(O)-M"-C(O)O-, -C(O)N(R')-, -N(R')C(O)-, -C(O)-, -C(S)-, -C(S)S-, -SC(S)-, -CH(OH)-, -P(O)(OR')O-, -S(O)2-, -SS-, an aryl group, and a heteroaryl group, where M" is a bond, 1-13 Alkyl or C 2-13 alkenyl, R 7 is C 1-3 Alkyl, C 2-3 alkenyl, and H; R 8 is C 3-6 selected from the group consisting of carbocycles and heterocycles; R 9 H, CN, NO2, C 1-6 Alkyl, -OR, -S(O)2R, -S(O)2N(R)2, C 2-6 Alkenyl, C 3-6 selected from the group consisting of carbocycles and heterocycles; R 10 is H, OH, C 1-3 Alkyl, and C 2-3 alkenyl, Each R is C 1-6 Alkyl, C 1-3 Alkyl-aryl, C 2-3 Alkenyl, (CH2) q OR * and H, each q is independently selected from 1, 2, and 3; Each R' is independently C 1-18 Alkyl, C 2-18 Alkenyl, -R * is selected from the group consisting of YR″, -YR″, and H; Each R" is independently 3-15 Alkyl and C 3-15 alkenyl, Each R * is independently 1-12 Alkyl and C 2-12 alkenyl, Each Y is independently C 3-6 is a carbocyclic ring, each X is independently selected from the group consisting of F, Cl, Br, and I; and m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13, and 4 But -(CH2) n Q, -(CH2) n When CHQR, -CHQR, or -CQ(R), (i) when n is 1, 2, 3, 4 or 5, Q is not -N(R), or (ii) when n is 1 or 2, Q is not a 5-, 6-, or 7-membered heterocycloalkyl.

[0209] In some embodiments, a subset of compounds of formula (IL-I) is represented by formula (IL-IA):

[0210] [ka]

[0211] or an N-oxide thereof, or a salt or isomer thereof, wherein l is selected from 1, 2, 3, 4, and 5; m is selected from 5, 6, 7, 8, and 9; M1 is a bond or M'; and R 4 is hydrogen, unsubstituted C 1-3 Alkyl, -(CH2) o C(R 10 )2(CH2) n-o Q, -C(O)NQR, or -(CH2) n Q, where Q is OH, -NHC(S)N(R), -NHC(O)N(R), -N(R)C(O)R, -N(R)S(O)R, -N(R)R 8 , -NHC(=NR 9 )N(R)2, -NHC(=CHR 9 )N(R)2, -OC(O)N(R)2, -N(R)C(O)OR, -(CH2) n N(R), heteroaryl, or heterocycloalkyl; M and M' are independently selected from -C(O)O-, -OC(O)-, -OC(O)-M"-C(O)O-, -C(O)N(R')-, -P(O)(OR')O-, -SS-, an aryl group, and a heteroaryl group; and R 2 and R 3 are independently H, C 1-14 Alkyl, and C 2-14 alkenyl. For example, m is 5, 7, or 9. For example, Q is OH, -NHC(S)N(R)2, or -NHC(O)N(R)2.

[0212] In some embodiments, Q is -N(R)C(O)R, or -N(R)S(O)R. In some embodiments, a subset of compounds of formula (I) is represented by formula (IL-IB):

[0213] [ka]

[0214] or an N-oxide thereof, or a salt or isomer thereof, wherein all variables are as defined herein. In some embodiments, m is selected from 5, 6, 7, 8, and 9; R is hydrogen, unsubstituted C 1-3 Alkyl, or -(CH2) n Q, where Q is OH, -NHC(S)N(R), -NHC(O)N(R), -N(R)C(O)R, -N(R)S(O)R, -N(R)R, -NHC(=NR)N(R), -NHC(=CHR)N(R), -OC(O)N(R), -N(R)C(O)OR, heteroaryl, or heterocycloalkyl; M and M' are independently selected from -C(O)O-, -OC(O)-, -OC(O)-M"-C(O)O-, -C(O)N(R')-, -P(O)(OR')O-, -SS-, an aryl group, and a heteroaryl group; and R and R are independently selected from H, C, 1-14 Alkyl, and C 2-14 In some embodiments, Q is selected from the group consisting of alkenyl. In some embodiments, m is 5, 7, or 9. In some embodiments, Q is OH, -NHC(S)N(R)2, or -NHC(O)N(R)2. In some embodiments, Q is -N(R)C(O)R, or -N(R)S(O)R.

[0215] In some embodiments, a subset of compounds of formula (IL-I) is represented by formula (IL-II):

[0216] [ka]

[0217] or an N-oxide thereof, or a salt or isomer thereof, wherein l is selected from 1, 2, 3, 4, and 5; M1 is a bond or M'; and R 4 is hydrogen, unsubstituted C 1-3 Alkyl, -(CH2) o C(R 10 )2(CH2) n-o Q, -C(O)NQR, or -(CH2) n Q, where n is 2, 3, or 4, and Q is OH, -NHC(S)N(R), -NHC(O)N(R), -N(R)C(O)R, -N(R)S(O)R, -N(R)R 8 , -NHC(=NR 9 )N(R)2, -NHC(=CHR 9 )N(R)2, -OC(O)N(R)2, -N(R)C(O)OR, -(CH2) n N(R), heteroaryl, or heterocycloalkyl; M and M' are independently selected from -C(O)O-, -OC(O)-, -OC(O)-M"-C(O)O-, -C(O)N(R')-, -P(O)(OR')O-, -SS-, an aryl group, and a heteroaryl group; and R 2 and R 3 are independently H, C 1-14 Alkyl, and C 2-14 alkenyl.

[0218] In some embodiments, the compound of formula (IL-I) is represented by the formula (IL-IIa):

[0219] [ka]

[0220] or an N-oxide thereof, or a salt or isomer thereof, wherein R4 is as described herein. In some embodiments, the compound of formula (IL-I) has the formula (IL-IIb):

[0221] [ka]

[0222] or an N-oxide thereof, or a salt or isomer thereof, wherein R4 is as described herein. In some embodiments, the compound of formula (IL-I) has the formula (IL-IIc) or (IL-Ile):

[0223] [ka]

[0224] or an N-oxide thereof, or a salt or isomer thereof, wherein R4 is as described herein. In some embodiments, the compound of formula (IL-I) has the formula (IL-IIf):

[0225] [ka]

[0226] or an N-oxide thereof, or a salt or isomer thereof, wherein M is -C(O)O- or -OC(O)-; M" is C 1-6 Alkyl or C 2-6 alkenyl, and R and R are independently 5-14 Alkyl and C 5-14 alkenyl, where n is selected from 2, 3, and 4.

[0227] In a further embodiment, the compound of formula (IL-I) has the formula (IL-IId)

[0228] [ka]

[0229] or an N-oxide thereof, or a salt or isomer thereof, where n is 2, 3, or 4, and m, R', R", and R2-R6 are as described herein. In some embodiments, each of R2 and R3 is independently selected from the group consisting of C 5-14 Alkyl and C 5-14 alkenyl.

[0230] In a further embodiment, the compound of formula (IL-I) has the formula (IL-IIg):

[0231] [ka]

[0232] or an N-oxide thereof, or a salt or isomer thereof, wherein l is selected from 1, 2, 3, 4, and 5; m is selected from 5, 6, 7, 8, and 9; M1 is a bond or M'; M and M' are independently selected from -C(O)O-, -OC(O)-, -OC(O)-M"-C(O)O-, -C(O)N(R')-, -P(O)(OR')O-, -SS-, an aryl group, and a heteroaryl group; and R2 and R3 are independently selected from H, C, or an N-oxide thereof, or a salt or isomer thereof. 1-14 Alkyl, and C 2-14 In some embodiments, M″ is selected from the group consisting of C 1-6 Alkyl (e.g., C 1-4 Alkyl) or C 2-6 Alkenyl (e.g., C 2-4 alkenyl). In some embodiments, R2 and R3 are independently C 5-14 Alkyl and C 5-14 alkenyl.

[0233] In some embodiments, the ionizable lipid is one or more of the compounds described in U.S. Application Nos. 62 / 220,091, 62 / 252,316, 62 / 253,433, 62 / 266,460, 62 / 333,557, 62 / 382,740, 62 / 393,940, 62 / 471,937, 62 / 471,949, 62 / 475,140, ​​and 62 / 475,166, and PCT Application No. PCT / US2016 / 052352.

[0234] In some embodiments, the ionizable lipid is selected from compounds 1-280 described in US Application No. 62 / 475,166. In some embodiments, the ionizable lipid is

[0235] [ka]

[0236] or a salt thereof. In some embodiments, the ionizable lipid is

[0237] [ka]

[0238] or a salt thereof. In some embodiments, the ionizable lipid is

[0239] [ka]

[0240] or a salt thereof. In some embodiments, the ionizable lipid is

[0241] [ka]

[0242] or a salt thereof. In some embodiments, the ionizable lipid is one or more of the compounds described in US Application Nos. 62 / 733,315 and 62 / 798,874.

[0243] In some embodiments, the ionizable lipid has the formula (IL-IIh):

[0244] [ka]

[0245] or an N-oxide thereof, or a salt or isomer thereof, wherein R 1 is C 5-30 Alkyl, C 5-20 Alkenyl, -R * -YR", -YR", and -R"M'R'; R 2 and R 3 are independently H, C 1-14 Alkyl, C 2-14 Alkenyl, -R * YR”, -YR”, and -R * OR” or R 2 and R 3 together with the atom to which they are attached form a heterocyclic or carbocyclic ring, Each R 5 are independently OH, C 1-3 Alkyl, C 2-3 alkenyl, and H; Each R 6 are independently OH, C 1-3 Alkyl, C 2-3 alkenyl, and H; M and M' are independently selected from -C(O)O-, -OC(O)-, -OC(O)-M"-C(O)O-, -C(O)N(R')-, -N(R')C(O)-, -C(O)-, -C(S)-, -C(S)S-, -SC(S)-, -CH(OH)-, -P(O)(OR')O-, -S(O)2-, -SS-, an aryl group, and a heteroaryl group, where M" is a bond, 1-13 Alkyl or C 2-13 alkenyl, R 7 is C 1-3 Alkyl, C 2-3 alkenyl, and H; Each R is independently H, C 1-3 Alkyl, and C 2-3 alkenyl, R N is H or C 1-3 is alkyl, Each R' is independently C 1-18 Alkyl, C 2-18 Alkenyl, -R * is selected from the group consisting of YR″, -YR″, and H; Each R" is independently 3-15 Alkyl and C 3-15 alkenyl, Each R * is independently 1-12 Alkyl and C 2-12 alkenyl, Each Y is independently C 3-6 is a carbocyclic ring, each X is independently selected from the group consisting of F, Cl, Br, and I; X a and X b are each independently O or S; R 10 is H, halo, -OH, R, -N(R)2, -CN, -N3, -C(O)OH, -C(O)OR, -OC(O)R, -OR, -SR, -S(O)R, -S(O)OR, -S(O)2OR, -NO2, -S(O)2N(R)2, -N(R)S(O)2R, -NH(CH2) t1N(R)2, -NH(CH2) p1 O(CH2) q1 N(R)2, -NH(CH2) s1 OR, -N((CH2) s1 OR)2, -N(R)-carbocycle, -N(R)-heterocycle, -N(R)-aryl, -N(R)-heteroaryl, -N(R)(CH2) t1 -carbocycle, -N(R)(CH2) t1 -Heterocycle, -N(R)(CH2) t1 -Aryl, -N(R)(CH2) t1 - selected from the group consisting of heteroaryl, carbocycle, heterocycle, aryl and heteroaryl; m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13; n is selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; r is 0 or 1; t l is selected from 1, 2, 3, 4, and 5; p l is selected from 1, 2, 3, 4, and 5; q l is selected from 1, 2, 3, 4, and 5; and s l is selected from 1, 2, 3, 4, and 5.

[0246] In some embodiments, the ionizable lipid has the formula (IL-IIi):

[0247] [ka]

[0248] or an N-oxide thereof, or a salt or isomer thereof, wherein R 1a and R 1b is independently 1-14 Alkyl and C 2-14 alkenyl, and R 2 and R 3 is independently1-14 Alkyl, C 2-14 Alkenyl, -R * YR”, -YR”, and -R * OR” or R 2 and R 3 together with the atoms to which they are attached form a heterocyclic or carbocyclic ring.

[0249] In some embodiments, the ionizable lipid has the formula (IL-IIj):

[0250] [ka]

[0251] or an N-oxide thereof, or a salt or isomer thereof, l is selected from 1, 2, 3, 4, and 5; M1 is a bond or M'; R 2 and R 3 , H, C 1-14 Alkyl, and C 2-14 alkenyl.

[0252] In some embodiments, the ionizable lipid has the formula (IL-IIk):

[0253] [ka]

[0254] or an N-oxide thereof, or a salt or isomer thereof, l is selected from 1, 2, 3, 4, and 5; M1 is a bond or M'; R a’ and R b’ is C 1-14 Alkyl and C 2-14 alkenyl, R 2 and R 3 is C1-14 Alkyl and C 2-14 alkenyl.

[0255] In some embodiments, the ionizable lipid is

[0256] [ka]

[0257] or a salt thereof. In some embodiments, the ionizable lipid of the present disclosure has the formula (IL-III):

[0258] [ka]

[0259] or a salt or isomer thereof, wherein W is

[0260] [ka]

[0261] and Ring A is

[0262] [ka]

[0263] and t is 1 or 2; A1 and A2 are each independently selected from CH or N; Z is CH2 or absent, where when Z is CH2, dashed lines (1) and (2) each represent a single bond, and when Z is absent, dashed lines (1) and (2) are both absent; R1, R2, R3, R4, and R5 are independently C 5-20 Alkyl, C5-20 Alkenyl, -R"MR', -R * YR”, -YR”, and -R * OR" R x1 and R x2 are each independently H or C 1-3 is alkyl, each M is independently selected from the group consisting of -C(O)O-, -OC(O)-, -OC(O)O-, -C(O)N(R')-, -N(R')C(O)-, -C(O)-, -C(S)-, -C(S)S-, -SC(S)-, -CH(OH)-, -P(O)(OR')O-, -S(O)2-, -C(O)S-, -SC(O)-, an aryl group, and a heteroaryl group; M * is C1-C6 alkyl, W 1 and W 2 are each independently selected from the group consisting of -O- and -N(R6)-; Each R6 is independently H or C 1-5 is selected from the group consisting of alkyl, X 1 , X 2 , and X 3 are independently a bond, -CH2-, -(CH2)2-, -CHR-, -CHY-, -C(O)-, -C(O)O-, -OC(O)-, -(CH2) n -C(O)-, -C(O)-(CH2) n -, -(CH2) n -C(O)O-, -OC(O)-(CH2) n -, -(CH2) n -OC(O)-, -C(O)O-(CH2) n is selected from the group consisting of -, -CH(OH)-, -C(S)-, and -CH(SH)-; Each Y is independently C 3-6 is a carbocyclic ring, Each R * is independently 1-12 Alkyl and C 2-12 alkenyl, Each R is independently C 1-3 Alkyl and C3-6 is selected from the group consisting of carbocycles; Each R' is independently C 1-12 Alkyl, C 2-12 alkenyl, and H; Each R" is independently 3-12 Alkyl, C 3-12 Alkenyl and -R * MR′, and n is an integer from 1 to 6, In the formula, ring A is

[0264] [ka]

[0265] If i)X 1 , X 2 , and X 3 At least one of is not -CH2-, and / or ii) At least one of R1, R2, R3, R4, and R5 is -R"MR'.

[0266] In some embodiments, the compound has the formula (IL-IIIa1)-(IL-IIIa8):

[0267] [ka]

[0268] Either: In some embodiments, the ionizable lipid is one or more of the compounds described in U.S. Application Nos. 62 / 271,146, 62 / 338,474, and 62 / 413,345, and PCT Application No. PCT / US2016 / 068300.

[0269] In some embodiments, the ionizable lipid is selected from compounds 1-156 described in US Application No. 62 / 519,826. In some embodiments, the ionizable lipid is selected from compounds 1-16, 42-66, 68-76, and 78-156 described in U.S. Application No. 62 / 519,826.

[0270] In some embodiments, the ionizable lipid is

[0271] [ka]

[0272] or a salt thereof. The central amine moiety of the lipid represented by formula (IL-1), (IL-IA), (IL-IB), (IL-II), (IL-IIa), (IL-IIb), (IL-IIc), (IL-IId), (IL-IIe), (IL-IIf), (IL-IIg), (IL-III), (IL-IIIal), (IL-IIIa2), (IL-IIIa3), (IL-IIIa4), (IL-IIIa5), (IL-IIIa6), (IL-IIIa7), or (IL-IIIa8) can be protonated at physiological pH. Thus, the lipid can have a positive charge or a partial positive charge at physiological pH. Such lipids can be called cationic or ionic (amino) lipids. The lipid can also be zwitterionic, i.e., a neutral molecule having both positive and negative charges.

[0273] Polyethylene glycol (PEG) lipids As used herein, the term "PEG lipid" refers to a polyethylene glycol (PEG) modified lipid. Non-limiting examples of PEG lipids include PEG-modified phosphatidylethanolamine and phosphatidic acid, PEG-ceramide conjugates (e.g., PEG-CerC14 or PEG-CerC20), PEG-modified dialkylamine, and PEG-modified 1,2-diacyloxypropan-3-amine. Such lipids are also referred to as PEGylated lipids. In some embodiments, the PEG lipid can be a PEG-c-DOMG, PEG-DMG, PEG-DLPE, PEG-DMPE, PEG-DPPC, or PEG-DSPE lipid.

[0274] In some embodiments, PEG lipids include, but are not limited to, 1,2-dimyristoyl-sn-glycerol methoxypolyethylene glycol (PEG-DMG), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)] (PEG-DSPE), PEG-disterylglycerol (PEG-DSG), PEG-dipalmetyl, PEG-dioleyl, PEG-distearyl, PEG-diacylglycamide (PEG-DAG), PEG-dipalmitoylphosphatidylethanolamine (PEG-DPPE), or PEG-1,2-dimyristyloxalpropyl-3-amine (PEG-c-DMA).

[0275] In some embodiments, the PEG lipid is selected from the group consisting of PEG-modified phosphatidylethanolamines, PEG-modified phosphatidic acids, PEG-modified ceramides, PEG-modified dialkylamines, PEG-modified diacylglycerols, PEG-modified dialkylglycerols, and mixtures thereof.

[0276] In some embodiments, the lipid portion of the PEG-lipid has a molecular weight of about C 14 ~About C 22 , preferably about C 14 ~About C 16In some embodiments, the PEG moiety, e.g., mPEG-NH2, has a size of about 1000, 2000, 5000, 10,000, 15,000, or 20,000 daltons. In some embodiments, the PEG lipid is PEG 2k -DMG.

[0277] In some embodiments, the lipid nanoparticles described herein can include a PEG lipid that is a non-diffusible PEG. Non-limiting examples of non-diffusible PEG include PEG-DSG and PEG-DSPE.

[0278] PEG lipids are described in U.S. Pat. No. 8,158,601 and International Publication WO2015 / 130584. A2, which are incorporated herein by reference in their entireties.

[0279] Generally, some of the other lipid components (e.g., PEG lipids) of the various formulas described herein can be synthesized as described in International Patent Application PCT / US2016 / 000129, entitled "Compositions and Methods for Delivery of Therapeutic Agents," filed December 10, 2016, which is incorporated herein by reference in its entirety.

[0280] PEG lipid is a lipid modified with polyethylene glycol.PEG lipid can be selected from the non-limiting group including PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol, PEG-modified dialkylglycerol, and mixtures thereof. In some embodiments, PEG lipid can be PEG-c-DOMG, PEG-DMG, PEG-DLPE, PEG-DMPE, PEG-DPPC, or PEG-DSPE lipid.

[0281] In some embodiments, the PEG lipids useful in the present invention may be PEGylated lipids described in International Publication WO2012099755, the contents of which are incorporated herein by reference in their entirety. Any of these exemplary PEG lipids described herein may be modified to include hydroxyl groups on the PEG chain. In some embodiments, the PEG lipid is a PEG-OH lipid. As generally defined herein, a "PEG-OH lipid" (also referred to herein as a "hydroxy-PEGylated lipid") is a PEGylated lipid having one or more hydroxyl (-OH) groups on the lipid. In some embodiments, the PEG-OH lipid includes one or more hydroxyl groups on the PEG chain. In some embodiments, the PEG-OH or hydroxy-PEGylated lipid includes an -OH group at the end of the PEG chain. Each possibility represents a separate embodiment of the present invention.

[0282] In some embodiments, the PEG lipid useful in the present invention is a compound of formula (PL-I). Provided herein are compounds of formula (PL-I):

[0283] [ka]

[0284] or a salt thereof, wherein R 3 -OR O and R O is hydrogen, an optionally substituted alkyl, or an oxygen protecting group; r is an integer from 1 to 100, inclusive; L 1 is optionally replaced by C 1-10 alkylene, wherein optionally substituted C 1-10 At least one methylene of the alkylene is optionally substituted carbocyclylene, optionally substituted heterocyclylene, optionally substituted arylene, optionally substituted heteroarylene, O, N(R N), S, C(O), C(O)N(R N ), N.R. N C(O), C(O)O, OC(O), OC(O)O, -OC(O)N(R N ), N.R. N C(O)O, or NR N C(O)N(R N ) and are independently replaced by D is a moiety obtained by click chemistry or a moiety cleavable under physiological conditions; m is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; A is the formula

[0285] [ka]

[0286] and L 2 Each instance of is independently a bond or an optionally substituted C 1-6 alkylene, wherein optionally substituted C 1-6 One methylene unit of the alkylene is optionally O, N(R N ), S, C(O), C(O)N(R N ), N.R. N C(O), C(O)O, OC(O), OC(O)O, OC(O)N(R N ), N.R. N C(O)O, or NR N C(O)N(R N ), R 2 Each instance of is independently optionally substituted C 1-30 Alkyl, optionally substituted C 1-30 alkenyl, or optionally substituted C 1-30 alkynyl, optionally where R 2 one or more methylene units of optionally substituted carbocyclylene, optionally substituted heterocyclylene, optionally substituted arylene, optionally substituted heteroarylene, N(RN ), O, S, C(O), C(O)N(R N ), N.R. N C(O), NR N C(O)N(R N ), C(O)O, OC(O), OC(O)O, OC(O)N(R N ), N.R. N C(O)O, C(O)S, SC(O), C(=NR N ), C(=NR N )N(R N ), -NR N C(=NR N ), N.R. N C(=NR N )N(R N ), C(S), C(S)N(R N ), N.R. N C(S), NR N C(S)N(R N ), S(O), -OS(O), S(O)O, OS(O)O, OS(O)2, S(O)2O, OS(O)2O, N(R N )S(O), S(O)N(R N ), -N(R N )S(O)N(R N ), OS(O)N(R N ), N(R N )S(O)O, S(O)2, N(R N )S(O)2, S(O)2N(R N ), -N(R N )S(O)2N(R N ), OS(O)2N(R N ), or N(R N )S(O)2O, R N each instance of is independently hydrogen, an optionally substituted alkyl, or a nitrogen protecting group; Ring B is an optionally substituted carbocyclyl, an optionally substituted heterocyclyl, an optionally substituted aryl, or an optionally substituted heteroaryl; p is 1 or 2.

[0287] In some embodiments, the compound of formula (PL-I) is a PEG-OH lipid (i.e., R 3 -OR O and R O is hydrogen). In some embodiments, the compound of formula (PL-I) has the formula (PL-I-OH)

[0288] [ka]

[0289] or its salt. In some embodiments, the PEG lipids useful in the present invention are PEGylated fatty acids. In some embodiments, the PEG lipids useful in the present invention are compounds of formula (PL-II). Provided herein are compounds of formula (PL-II)

[0290] [ka]

[0291] or a salt thereof, wherein R 3 -OR O and R O is hydrogen, an optionally substituted alkyl, or an oxygen protecting group; r is an integer from 1 to 100, inclusive; R 5 is optionally replaced by C 10-40 Alkyl, optionally substituted C 10-40 alkenyl, or optionally substituted C 10-40 alkynyl, and optionally R 5 One or more methylene groups in the formula (I) are optionally substituted carbocyclylene, optionally substituted heterocyclylene, optionally substituted arylene, optionally substituted heteroarylene, N(R N ), O, S, C(O), C(O)N(R N ), -NRN C(O), NR N C(O)N(R N ), C(O)O, OC(O), OC(O)O, OC(O)N(R N ), N.R. N C(O)O, C(O)S, -SC(O), C(=NR N ), C(=NR N )N(R N ), N.R. N C(=NR N ), N.R. N C(=NR N )N(R N ), C(S), C(S)N(R N ), -NR N C(S), NR N C(S)N(R N ), S(O), OS(O), S(O)O, OS(O)O, OS(O)2, S(O)2O, OS(O)2O, N(R N )S(O), S(O)N(R N ), N(R N )S(O)N(R N ), OS(O)N(R N ), N(R N )S(O)O, S(O)2, N(R N )S(O)2, -S(O)2N(R N ), N(R N )S(O)2N(R N ), OS(O)2N(R N ), or N(R N )S(O)2O, and R N Each instance of is independently hydrogen, an optionally substituted alkyl, or a nitrogen protecting group.

[0292] In some embodiments, the compound of formula (PL-II) has the formula (PL-II-OH)

[0293] [ka]

[0294] or a salt thereof. In some embodiments, r is 45. In yet another embodiment, the compound of formula (PL-II)

[0295] [ka]

[0296] or a salt thereof. In some embodiments, the compound of formula (PL-II)

[0297] [ka]

[0298] It is. In some embodiments, the PEG lipid can be one or more of the PEG lipids described in U.S. Patent Application No. 62 / 520,530. In some embodiments, the PEG lipid can be represented by the formula (PL-III):

[0299] [ka]

[0300] or a salt or isomer thereof, wherein s is an integer from 1 to 100. In some embodiments, the PEG lipid has the formula:

[0301] [ka]

[0302] It is a compound of the formula: structural lipids As used herein, the term "structured lipid" refers to a sterol and also to lipids that contain a sterol moiety.

[0303] The incorporation of structured lipids into lipid nanoparticles may help to mitigate the aggregation of other lipids within the particle. The structured lipids may be selected from the group including, but not limited to, cholesterol, fecosterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatidine, tomatine, ursolic acid, alpha-tocopherol, hopanoids, phytosterols, steroids, and mixtures thereof. In some embodiments, the structured lipid is a sterol. As defined herein, "sterol" is a subgroup of steroids consisting of steroid alcohols. In some embodiments, the structured lipid is a steroid. In some embodiments, the structured lipid is cholesterol. In some embodiments, the structured lipid is an analog of cholesterol. In some embodiments, the structured lipid is alpha-tocopherol.

[0304] In some embodiments, the structured lipid may be one or more of the structured lipids described in US Patent Application No. 62 / 520,530. Phospholipids Phospholipids may assemble into one or more lipid bilayers. Generally, phospholipids comprise a phospholipid moiety and one or more fatty acid moieties.

[0305] The phospholipid moiety can be selected from the non-limiting group consisting of, for example, phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidylserine, phosphatidic acid, 2-lysophosphatidylcholine, and sphingomyelin.

[0306] The fatty acid moiety can be selected from the non-limiting group consisting of, for example, lauric acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, linoleic acid, alpha-linolenic acid, erucic acid, phytanic acid, arachidic acid, arachidonic acid, eicosapentaenoic acid, behenic acid, docosapentaenoic acid, and docosahexaenoic acid.

[0307] Certain phospholipids can promote fusion to membrane.In some embodiments, cationic phospholipids can interact with one or more negatively charged phospholipids of membrane (e.g., cell membrane or intracellular membrane).Fusion of phospholipid to membrane allows one or more elements (e.g., therapeutic agent) of lipid-containing composition to pass through membrane, for example, allows one or more elements to be delivered to target tissue.

[0308] Non-natural phospholipid species are also contemplated, including natural species with modifications and substitutions, including branching, oxidation, cyclization, and alkynes. In some embodiments, phospholipids can be functionalized or crosslinked with one or more alkynes (e.g., alkenyl groups in which one or more double bonds are replaced with triple bonds). Under appropriate reaction conditions, the alkyne groups can undergo copper-catalyzed cycloaddition upon exposure to azides.

[0309] Phospholipids include, but are not limited to, glycerophospholipids, such as phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidylglycerol, and phosphatidic acid. Phospholipids also include glycosphingolipids, such as sphingomyelin.

[0310] In some embodiments, phospholipids useful or potentially useful in the present invention are analogs or variants of DSPC. In some embodiments, phospholipids useful or potentially useful in the present invention are analogs or variants of DSPC.

[0311] [ka]

[0312] or a salt thereof, wherein Each R 1 are independently optionally substituted alkyl, or optionally, two R 1together with the intervening atoms form an optionally substituted monocyclic carbocyclyl or an optionally substituted monocyclic heterocyclyl, or optionally three R 1 together with the intervening atoms form an optionally substituted bicyclic carbocyclyl or an optionally substituted bicyclic heterocyclyl; n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; m is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; A is the formula

[0313] [ka]

[0314] and L 2 Each instance of is independently a bond or an optionally substituted C 1-6 alkylene, wherein optionally substituted C 1-6 A single methylene unit of an alkylene is -O-, -N(R N )-, -S-, -C(O)-, -C(O)N(R N )-, -NR N C(O)-, -C(O)O-, -OC(O)-, -OC(O)O-, -OC(O)N(R N )-, -NR N C(O)O- or -NR N C(O)N(R N )-, which is optionally replaced by Each instance of R2 independently represents an optionally substituted C 1-30 Alkyl, optionally substituted C 1-30 alkenyl, or optionally substituted C 1-30 alkynyl, optionally wherein one or more methylene units of R2 are optionally substituted carbocyclylene, optionally substituted heterocyclylene, optionally substituted arylene, optionally substituted heteroarylene, -N(R N)-, -O-, -S-, -C(O)-, -C(O)N(R N )-, -NR N C(O)-, -NR N C(O)N(R N )-, -C(O)O-, -OC(O)-, -OC(O)O-, -OC(O)N(R N )-, -NR N C(O)O-, -C(O)S-, -SC(O)-, -C(=NR N )-, -C(=NR N )N(R N )-, -NR N C(=NR N )-, -NR N C(=NR N )N(R N )-, -C(S)-, -C(S)N(R N )-, -NR N C(S)-, -NR N C(S)N(R N )-, -S(O)-, -OS(O)-, -S(O)O-, -OS(O)O-, -OS(O)2-, -S(O)2O-, -OS(O)2O-, -N(R N )S(O)-, -S(O)N(R N )-, -N(R N )S(O)N(R N )-, -OS(O)N(R N )-, -N(R N )S(O)O-, -S(O)2-, -N(R N )S(O)2-, -S(O)2N(R N )-, -N(R N )S(O)2N(R N )-, -OS(O)2N(R N )-, or -N(R N )S(O)2O-, R N each instance of is independently hydrogen, an optionally substituted alkyl, or a nitrogen protecting group; Ring B is an optionally substituted carbocyclyl, an optionally substituted heterocyclyl, an optionally substituted aryl, or an optionally substituted heteroaryl; and p is 1 or 2; However, this compound has the formula

[0315] [ka]

[0316] (In the formula, R 2 Each instance of is independently an unsubstituted alkyl, an unsubstituted alkenyl, or an unsubstituted alkynyl. It is not a compound of.

[0317] In some embodiments, the phospholipid can be one or more of the phospholipids described in US Patent Application No. 62 / 520,530. i) Modification of phospholipid head groups In some embodiments, phospholipids useful or potentially useful in the present invention include a modified phospholipid head group (e.g., a modified choline group). In some embodiments, the phospholipid with a modified head group is DSPC or an analog thereof with a modified quaternary amine. In some embodiments, in the embodiments of formula (PL-I), R 1 At least one of R is not methyl. 1 In some embodiments, the compound of formula (PL-I) has the formula:

[0318] [ka]

[0319] or a salt thereof, each t is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; each u is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; Each v is independently 1, 2, or 3.

[0320] In some embodiments, the compound of formula (PL-I) has the formula (PL-Ia):

[0321] [ka]

[0322] or a salt thereof. In some embodiments, phospholipids useful or potentially useful in the present invention contain a cyclic moiety instead of a glyceride moiety. In some embodiments, phospholipids useful in the present invention are DSPC or analogs thereof having a cyclic moiety instead of a glyceride moiety. In some embodiments, the compound of formula (PL-I) is represented by formula (PL-Ib):

[0323] [ka]

[0324] or a salt thereof. ii) Modification of the phospholipid tail In some embodiments, the phospholipids useful or potentially useful in the present invention include modified tails. In some embodiments, the phospholipids useful or potentially useful in the present invention are DSPCs or analogs thereof with modified tails. As described herein, a "modified tail" can be a shorter or longer aliphatic chain, a branched aliphatic chain, a substituted aliphatic chain, an aliphatic chain in which one or more methylenes are replaced with cyclic or heteroatomic groups, or any combination thereof. In some embodiments, the compound of (PL-I) is a compound of formula (PL-Ia), or a salt thereof, wherein R 2 At least one example of 2 Each example of 1-30 alkyl, where R 2one or more methylene units of optionally substituted carbocyclylene, optionally substituted heterocyclylene, optionally substituted arylene, optionally substituted heteroarylene, -N(R N )-, -O-, -S-, -C(O)-, -C(O)N(R N )-, -NR N C(O)-, -NR N C(O)N(R N )-, -C(O)O-, -OC(O)-, -OC(O)O-, -OC(O)N(R N )-, -NR N C(O)O-, -C(O)S-, -SC(O)-, -C(=NR N )-, -C(=NR N )N(R N )-, -NR N C(=NR N )-, -NR N C(=NR N )N(R N )-, -C(S)-, -C(S)N(R N )-, -NR N C(S)-, -NR N C(S)N(R N )-, -S(O)-, -OS(O)-, -S(O)O-, -OS(O)O-, -OS(O)2-, -S(O)2O-, -OS(O)2O-, -N(R N )S(O)-, -S(O)N(R N )-, -N(R N )S(O)N(R N )-, -OS(O)N(R N )-, -N(R N )S(O)O-, -S(O)2-, -N(R N )S(O)2-, -S(O)2N(R N )-, -N(R N )S(O)2N(R N )-, -OS(O)2N(R N )-, or -N(R N )S(O)2O- are independently replaced by . In some embodiments, the compound of formula (PL-I) has the formula (PL-Ic):

[0325] [ka]

[0326] or a salt thereof, wherein each x is independently an integer from 0 to 30, inclusive; and Each instance of G is independently an optionally substituted carbocyclylene, an optionally substituted heterocyclylene, an optionally substituted arylene, an optionally substituted heteroarylene, -N(R N )-, -O-, -S-, -C(O)-, -C(O)N(R N )-, -NR N C(O)-, -NR N C(O)N(R N )-, -C(O)O-, -OC(O)-, -OC(O)O-, -OC(O)N(R N )-, -NR N C(O)O-, -C(O)S-, -SC(O)-, -C(=NR N )-, -C(=NR N )N(R N )-, -NR N C(=NR N )-, -NR N C(=NR N )N(R N )-, -C(S)-, -C(S)N(R N )-, -NR N C(S)-, -NR N C(S)N(R N )-, -S(O)-, -OS(O)-, -S(O)O-, -OS(O)O-, -OS(O)2-, -S(O)2O-, -OS(O)2O-, -N(R N )S(O)-, -S(O)N(R N )-, -N(R N )S(O)N(R N )-, -OS(O)N(R N )-, -N(R N )S(O)O-, -S(O)2-, -N(R N )S(O)2-, -S(O)2N(R N )-, -N(R N)S(O)2N(R N )-, -OS(O)2N(R N )-, or -N(R N )S(O)2O-. Each possibility represents a separate embodiment of the present invention.

[0327] In some embodiments, phospholipids useful or potentially useful in the present invention include a modified phosphocholine moiety, in which the alkyl chain linking the quaternary amine to the phosphoryl group is not ethylene (e.g., n is not 2). Thus, in some embodiments, phospholipids useful or potentially useful in the present invention are compounds of formula (PL-I), where n is 1, 3, 4, 5, 6, 7, 8, 9, or 10. In some embodiments, compounds of formula (PL-I) have the following formula:

[0328] [ka]

[0329] or a salt thereof. Alternative lipids In some embodiments, alternative lipids are used in place of the phospholipids of the present disclosure. Non-limiting examples of such alternative lipids include:

[0330] [ka]

[0331] Equivalent Exemplary embodiments of devices, systems, and methods have been described herein. As noted elsewhere, these embodiments are described for illustrative purposes only and are not limiting. Other embodiments are possible and are within the scope of this disclosure and are apparent from the teachings contained herein. Thus, the breadth and scope of the present disclosure should not be limited by any of the above-described embodiments, but should be defined solely based on the claims supported by this disclosure and its equivalents. Furthermore, embodiments of the subject disclosure can include methods, systems, and devices that may further include any and all elements from other disclosed methods, systems, and devices, including any and all elements corresponding to the separation, focusing / concentration of target particles. In other words, elements from one or another disclosed embodiment can be replaced with elements from other disclosed embodiments. Furthermore, one or more features / elements of a disclosed embodiment may be removed and still result in patentable subject matter (resulting in even more embodiments of the subject disclosure). Correspondingly, some embodiments of the present disclosure may be patentably distinguished from one and / or another reference by specifically lacking one or more elements / features. In other words, a claim to a particular embodiment may include a negative limitation to specifically exclude one or more elements / features, resulting in an embodiment that is patentably distinct from the prior art that includes such features / elements.

Claims

[Claim 1] The invention described in the specification.

Citation Information

Patent Citations

  • Reaction mixing system for mixing and chemical reaction of at least two fluids

    EP2090353A1

  • Vortex mixer with back-streaming or reverse flow in discharge minimised

    GB2282546A

  • Method for centrifugal separation of gas by dis- persion and / or mixing thereof

    JP1992245991A

  • Fluid mixing method, micro-device and its fabricating method

    JP2008086889A

  • Emulsification device

    JP2009279507A